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ABSTRACT OF THESIS 
 
Synthesis of Dual Small Molecule Hybrids to Probe the Synergy between DNA Repair 
Enzymes and IDO1  
Indoleamine 2 3-dioxygenase (IDO) has recently been highlighted as a promising target 
for small molecule based immunotherapy. IDO is often coopted by various cancer cells to 
promote an immune-suppressive environment around tumors. DNA damage repair (DDR) 
enzymes have recently been targeted for inhibition to promote genetic instability and 
bolster immune recognition. DDR enzymes such as PARP and POLγ are common 
inhibition targets due to their direct effects on cellular function.  In the process of designing 
conjugate inhibitors of IDO and DDR enzymes, novel synthetic methodology was 
developed for the mild deprotection of N-Tert-butyloxycarbonyl (N-BOC) group from 
various amines. Conjugate inhibitors of IDO and PARP were synthesized using the parent 
molecules 1-MLT and Olaparib. The conjugate molecules showed more potent cytotoxicity 
in various cancer cell lines than their precursor molecules. The novel conjugate inhibitors 
could be used as probes to explore interplay between the PARP and IDO signaling 
pathways and elucidate any synergy or dependency between the two enzymes. 
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CHAPTER 1.  INDOLEAMINE 2,3-DIOXYGENASE AS A TARGET FOR IMMUNOMODULATION 
IN THE TUMOR MICRO-ENVIRONMENT 
1.1 IDO and Cancer 
Indoleamine 2,3-dioxygenase (IDO) has recently become a high profile target for 
immunotherapy in the fight against multiple types of cancer. Though often viewed as an 
immunosuppressing enzyme that modulates the adaptive immune system, IDO has been 
shown to be involved in the early stages of inflammation1. IDO’s immunomodulatory 
role varies between different types of cells, cancers, and pathogenic microenvironments, 
making it’s eventual effects hard to predict as well as unique to that particular 
environment1-3. Recent clinical trials have aimed to use small molecule inhibitors as a 
monotherapy or coupled with immune checkpoint antibodies and vaccines to target 
tumors prone to immune escape4. Though initial trials showed tumor reduction and 
promising response to IDO inhibition and combination therapy, recent failures in stage III 
clinical trials of pioneering IDO small molecule inhibitor therapies have left the field 
second guessing the efficacy of targeting IDO5, 6. Despite recent setbacks, IDO remains a 
key immunomodulatory enzyme that with further research could become a very useful 
tool in the fight against cancer. This introduction aims to summarize the method of 
action, current clinical targets, and in particular the potential hurdles and difficulties 
involved with tuning the immune response via IDO inhibition.  
  IDO is an heme containing enzyme that catalyzes the rate limiting step in the conversion 
of cellular tryptophan to kyurenine7. Tryptophan catabolism was first observerd to be 
elevated in cancer patients as early as the 1950’s. Munn, Mellor, and colleagues first 
described the active immune suppressive role of IDO in suppressing T-cell mediated 
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rejection of fetuses during pregnancy8. These discoveries led to the investigation of 
IDO’s role in the immune escape of tumors as well as autoimmune disorders and graft 
tolerance following transplantation9. IDO was shown to be expressed within the tissue of 
multiple different types of cancers as early as 2003 and multiple subsequent studies found 
a correlation between poor patient prognosis and limited lymphocyte migration to and 
infiltration of the tumor microenvironment10-13. It’s overexpression and activity have 
been studied in numerous types of gynecological cancers such as ovarian, vulvar, and 
cervical carcinomas14.   
IDO is commonly overexpressed in tumor milieu15. This overexpression characteristic 
varies between tissue and cell types and can cause varying outcomes15, 16. Overexpression 
of IDO has been correlated to a poor patient prognosis, indicating the large role IDO 
plays in tumor immune escape17. Within dendritic cells (DC), IDO has been found to be 
overexpressed near the edge of the inflammatory tissue microenvironment as well as 
within tumor draining lymph nodes (TDLN)9, 18. IDO is commonly found in multiple 
types of healthy epithelial cells as well as epithelial cells within the inflamed tumor 
milieu. Initial theories held that IDO was induced upon inflammation and acted as an 
adaptive immunosuppressive molecule. This theory is further supported by the fact that 
interferon gamma (INFγ), TGFβ, and various TLR ligands have been shown to 
upregulate IDO expression and activity with INFγ being the strongest inducer of IDO. 
Increased IDO expression within the tumor environment is also often due to mutations in 
the BIN-1 gene, a tumor suppressor gene that is commonly inactive or mutated in cancer 
cells19. Within the inflamed tumor environment IDO acts to suppress T-cell response and 
promote T-cell anergy through multiple methods. Downstream metabolites of IDO It 
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have been shown to inhibit the proliferation of NK cells as well as B cells20. Though it’s 
role as an immunosuppressant enzyme has been studied in depth and confirmed, recent 
studies have shed light on the role of IDO in the early stages of tumor growth and suggest 
a role for the enzyme in the onset of inflammation, lymphocyte proliferation and 
angiogenesis within the tumor1, 21. A suggested role in the induction of inflammation was 
shown by the presence and activity of IDO in inflamed tissues in the absence of cancer 
cells9. IDOKO cells also showed little response in terms of tumor formation in the absence 
of an inflammatory stimulant like INF-γ, showing that IDO has a multifunctional purpose 
in the growth and eventual immune escape of tumors22.  
1.2 IDO’s multiple roles and effects 
Outside of the cancer realm IDO is involved in immune system modulation throughout 
various organs. The complex signaling and effector pathways involving IDO often vary 
between different organ systems. In certain autoimmune diseases increased IDO function 
can promote tolerance and reduce inflammation. Peripheral autoreactive memory T cells 
show a decrease and eventual long-term cessation of multi-organ inflammation after INF-
γ stimulated induction of IDO by host APC’s23. In other autoimmune environments 
epithelial cells induce IDO to reign in autoreactivity. In allergic airway disease, 
inflammation triggered by activation of TLRs is suppressed by induction of IDO within 
the inflamed environment24. IDO has been implicated as a target for diseases such as 
Asthma, Atopy, and Graft verses Host Disease, in each case being induced to promote 
tolerance or reduce inflammatory cell functions25-30. Other scientist have explored 
inducing IDO overexpression or increasing IDO activity in an attempt to promote 
immune tolerance to various drugs31, 32.   
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Aberrant function of IDO has been implicated in multiple forms of virus-derived 
inflammatory diseases. IDO activity has been shown to play a role in Hepatitis C 
mediated cirrhosis of the liver, though the exact mechanism is only partially understood. 
The critical role of CD4+ T cells in the removal of the virus is hindered by IDO 
overexpression within hepatic cells. Similar to its role in cancer progression and tumor 
immune escape, the concurrent blunting of CD4+ cells and proliferation of Treg cells 
produces and state of chronic infection leading to cirrhosis33. Hepatocellular carcinoma 
experiences a tolerance profile similar to that of HCV induced cirrhosis, and is often 
induced by chronic HCV and HCB infection34. IDO-KO mice further highlighted the 
tolerance promoting properties of IDO when it was observed that the IDO knockout mice 
fed a high fat diet experience higher infiltration of macrophages and T-lymphocytes into 
the white adipose tissue within the liver, eventually leading to fibrosis of the liver 
tissue35.  Advanced human atherosclerotic plaque progression has also been linked to 
IDO mediated degradation of tryptophan with the root cause being and increase in 
macrophage infiltration of atheromatous core coupled with increased FOXp3 T-reg cell 
function and APC expression of more IDO36.  
A study in 2014 established a link between IDO and PARP in DNA repair and immune 
response to the tumor environment37. The researchers found that IDO mediated an 
immune independent tolerance to Oliparib, a small molecule PARP inhibitor, through 
modulation of downstream metabolites like NAD+37, 38. The kynurenine pathway is one 
of two mechanisms within the cell for production of NAD+, which is vital to PARP DNA 
repair activities37.  
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Endometrial cancer patients with higher expression levels of IDO experienced greater 
tumor progression and poor clinical outcome39. In a clinical trial of colorectal cancer 
patients high IDO expression was linked with decreased tumor infiltration of CD3+ 
Tcells and poor survival rates40. 
1.3 Effector Pathways 
IDO suppresses immune response and promotes immune escape of tumors through three 
main effector pathways41, 42. Depletion of cytosolic tryptophan leads to an increase in 
uncharged tRNA levels which begins a signaling pathway mediated by phosphorylation 
of the initiation factor EIF-2α by the stress response kinase GCN243. mTORC1 mediates 
cellular transcription in response to stimulation by growth factors or critical amino acid 
concentration levels1, 7, 44. The AHr is activated by downstream metabolites of tryptophan 
as well as other substrates and initiates cell signaling pathways that either stimulate 
regulatory t-cell function or perturb cytoxic T-cell function proliferation within the tumor 
environment45, 46. These three pathways account for the most investigated modes of 
action of IDO. While IDO action has been shown to play a role in other immune system 
regulatory pathways, they have not been investigated in depth and usually have not been 
investigated in multiply types of cancer. All three of these regulatory pathways are also 






The general control nonderepressible 2 kinase (GCN2) acts as an effector pathway for 
IDO by dampening the response of T cells within the tumor microenvironment. IDO, 
when active, reduces cellular tryptophan levels as well as tryptophan within the local 
tissue microenvironment. GCN2 primarily limits protein translation in nutrient deprived 
tissue but does upregulate the transcription factor LIP which in turn increases expression 
of NF-kβ, CHOP, and INFγ receptor while simultaneously decreasing production of IL-6, 
In a negative feedback loop fashion.  GCN2 is activated by binding to uncharged tRNA 
in amino acid starved cells47. Upon activation, GCN2 phosphorylates serine 51 on eIF2α, 
restricting translation within the cell and leading to arrest, apoptosis and anergy of CD-8+ 
T-cells48. GCN2 activation leads to cell cycle arrest within CD-8+ T cells43, 49 while 
simultaneously promoting differentiation of immature CD-4+ T-cells into regulatory T-
cells50 and activating immuno-suppressive activity in mature Treg cells51. IDO therefore 
causes suppression of the immune system when overexpressed by tumor cells. Though 
GCN2 blunts the translation of most mRNA it does increase the translation of others and 
leads to an increase in production of IL-6 the anti-inflammatory cytokine.  Some have 
argued that GCN2 is not the predominate force driving effector T cell non-proliferation 
during amino acid starvation and is also dispensable in exocellular amino acid sensing by 
T-cells47, 52. Therefore there is disagreement in the literature on whether or not IDO 
actually suppresses immune response via GCN2 due to the fact that GCN2KO mice show 
no symptoms of autoimmunity53. These discrepancies could play a crucial role in why 




1.3.2  MTORC1 
The master metabolic regulator (mTORC1) works in an opposite mode of action to 
GCN2. While tryptophan depletion activates GCN2, mTORC1 normal cellular response 
is inhibited during cellular stress and lack of nutrients. Normally mTOR functions when 
amino acids are sufficient, phosphorylating  transcription regulators like S6K1 and 
4EBP154. Depleting amino acids within the tumor milieu allows GCN2 and mTORC1 to 
work in concert, with GCN2 restricting transcription due to its activation and mTORC 
restricting transcription due to its deactivation. As tryptophan is depleted due to IDO 
function, mTOR is repressed which can lead to autophagy55. Some of the signaling 
pathways that report amino acid deficiency to mTOR also are involved in activation of 
and signaling to protein kinase C-θ (PKC-θ), which is involved in T cell receptor 
regulation56. 
mTORC1 and mTORC2’s roles have been implicated in cancer apart from the 
downstream affects of IDO57. mTORC1 is unique in the sense that it receives nutrient 
level signals as well as growth factor signals whereas mTORC2 only receives growth 
factor signals58, 59. mTORC1 is constitutively expressed due to a multitude of different 
oncogenes in various cancers59. Deregulation of mTORC1 function is found in nearly 
80% of cancers and the underlying cause often has nothing to do with increased IDO 
induction. That being said, inhibition of mTORC1 in multiple clinical trials by rapamycin 
or other inhibitors has not been shown to be effective in reducing tumor size. The 
findings of multiple studies show that while mTORC1 obviously plays a major role in 
Tumor immune escape and growth, it works in concert with other signaling pathways to 
exact this effect. The cross talk between the mTOR and GCN2 effector pathways of IDO 
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has not been studied in depth and continued investigation in this area could shed light 
other mechanisms of suppression as well as how tumor cells circumvent inhibition of 
IDO.  
1.3.3 AHr 
The aryl hydrocarbon receptor (AHr) is activated by Kynurenine, the product of IDO 
metabolization of tryptophan46, 60. AHr function promotes the differentiation of naïve 
CD4+ cells into forkhead box P3-positive (FOXP3+) Tregs while simultaneously 
repressing the production of TH17 cells61, 62. Binding of Kynurenine to AHR also leads to 
anergy of other effector T cells63. Upon activation, AHR travels to the nucleus where it 
works as a transcription factor inducing multiple immune suppressing genes63. Increased 
activity of AHr reduces T cell migration to the tumor microenvironment as well as blunts 
T-cell proliferation63. AHr has been shown to be constitutively expressed in multiple 
tumor cells64. Combined with an increase in IDO function, this heightened expression 
causes strong modulation of immune response and suppression of effector cells65. AHr 
studies in mouse models revealed that an AhR deficiency often led to autoimmunity 
whereas the constitutive expression of AhR can promote tumorigenesis66.  
The role of AHr in cancer is not strictly confined to regulation of immune response, and 
has been implicated in tumor cell proliferation, angiogenesis and metastasis as well66-68. 
Kynurenine is not the only ligand that can activate the AHr’s immune-modulatory 
functions and different types of cancers hijack the AHr’s functions through various 
mutations69.  Multiple other ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
6-formylindolo[3,2-b]carbazole (FICZ), and 2-(1′H-indole-3′-carbonyl)-thiazole-4-
carboxylic acid methyl ester (ITE) also have strong affinity for AHr66, 70. A common 
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theme between all three effector pathways of IDO is the fact that different malignancies 
coopt the same immuno-regulatory pathways through different mechanisms. It is also not 
uncommon for a cancer cells to manipulate a specific cellular function through multiple 
mechanisms, making inhibition of a singular upstream pathway with the intended result 
being a loss of AHr function or upregulation ineffective.   
1.4 Induction of IDO 
IFN-γ is the most common inducer of IDO within antigen presenting cells (APC). IFN-γ 
mediates IDO expression through the Janus Kinase (JAK)/ signal transducer and activator 
of transcription (STAT) pathway71. The induction of IDO can be further potentiated by 
addition of other inflammatory cytokines and soluble molecules such as TNF-α, IL-10, 
and IL-1β41, 71.  IDO has been shown to both increase production of IL-6 through an AHr 
mediated pathway, and be induced by IL-6 signaling within the cell, indicating a self-
sustaining loop for IDO expression69. Different types of Dendritic cells and macrophages 
respond to different stimuli when it comes to the induction of IDO. For example, IFN-γ 
promotes CD8+ DC’s mediated inhibition of CD8- DC antigen presentation and blocks 
it’s response to IL-12 stimulation but has no effect on CD8- DCs in the absence of their 
CD8+ counterparts72. Because an assortment of genes commonly called IFN-stimulated 
genes(ISGs) can stimulate both immunity and tumor specific tolerance, IDO expression is 
often upregulated in response to beneficial inflammation73 but can also be upregulated 
due to tumor promoting chronic inflammation74. Induction of IDO within the tumor 
environment can come from a plethora of different stimuli as well as cells. Within 
monocyte derived dendritic cells and some other APC’s, PGE2 induces expression of 
IDO via a signaling pathway through the EP2 receptor which activates PKA75. This 
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signaling pathway is only efficient in inducing IDO expression when combined with a 
TLR antagonist or substrate binding to the TNF-R75.  
A few different IDO regulatory pathways have been investigated through the literature. 
iNOS which is also activated upon INF-γ stimulation, produces nitric oxide, a direct 
inhibitor of IDO76. NO not only inhibits IDO function but leads to degradation of cellular 
IDO through a proteasome mediated mechanism76. Intracellular SOCS3 has been shown 
to bind to IDO and signal the complex for ubiquitinization also resulting in proteasome 
mediated degradation77. SOCS3 also functions to limit the tolerogenic functions of IDO. 
In some cancers migration of lymphocytes to the tumor milieu can induce expression of 
IDO. INF-γ stimulates IDO upregulation, CTLA-4 expression, and recruitment of FOXP3 
regulatory T-cells to the tumor environment after infiltration of cytoxic T-cells78. This 
event indicates a reactionary role of multiple immuno-suppressive effector molecules 
after an increase in inflammation mediated by normal immune system function as 
opposed to tumor cells coopting tolerogenic mechanism for immune escape78. Inhibition 
of IDO with 1-methyl-D-Tryptophan actually stimulates increased expression of IDO in 
an attempt to reduce chronic inflammation.     
1.5 Chemical Conversion of Tryptophan 
 IDO is a monomeric heme-containing enzyme that catalyzes the oxidative 
cleavage of L-tryptophan to Kynurenine60. In 2006 the crystal structure of the IDO 
molecule complexed with its ligand was published and a mechanism of action was 
proposed79. Proton extraction by the dioxygen species attached to the iron center of the 
heme ring is followed by oxidative cleavage of the alkene located on the pyrole ring of 
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the indole moiety. IDO initially converts L-tryptophan into N-formal-L-kynurenine, 
while Formamidase then catalyzes the conversion of N-formal-L-kynurenine to L-
kynurenine, which is the substrate molecule for multiple immunoregulatory pathways79-
81. Kynurenine can then be further converted into multiple different downstream 
metabolites that each play important roles within the cell. The kynurenine pathway is the 
de-novo pathway for the production of NAD+ within the cell, which is a key metabolite 
involved in many redox reactions within the cell61, 80. Critical enzymes like PARP require 
NAD+ for its DNA damage repair mechanism82.  
 The inhibition of IDO can be accomplished by either competitive inhibition of the 
IDO enzyme or inhibition of downstream enzymes within the kynurenine pathway. 
Though IDO1 and IDO2 catalyze the conversion of tryptophan, IDO2 is less active in 
tryptophan conversion and has tighter substrate restrictions80, 83. TDO is similar in 
activity to IDO81, but lacks structural homology and is found primarily in the liver and 
brain whereas IDO1 is found in multiple different types of peripheral tissues and cells80. 
For the purposes of this review only inhibition of the IDO1 enzyme will be discussed.  
1.6 IDO1 Inhibitors 
 In the past two decades, a host of different small molecule IDO1 inhibitors have 
been discovered with some compounds having IC50 values in the low nanomolar range84. 
Early inhibitors of IDO1 were derivations of tryptophan maintaining the indole core85. 1-
methyl-L-Tryptophan and its enantiomer are probably the most studied tryptophan 
derivatives54, 85, 86. Though Its binding affinity to the IDO active site and inhibitory 
affects are relatively weak compared to some other inhibitors, Its binding modes were 
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characterized early and it has been used to probe IDO signaling through the AHr and the 
MTORc54, 87. While trying to inhibit IDO activity using 1MDT, researchers surprisingly 
discovered that 1MDT can stimulate expression of IDO, a counterproductive result that is 
particularly relevant to many other IDO inhibitors currently in clinical trials88. The IDO 
inhibitor 5-((1H-indol-3-yl)methyl)-3-methyl-2-thioximidazolidin-4-one (MTH-trp), 
commonly known as Necrostatin-1, has an inhibitory constant Ki of 12 μM and also 
exhibits pluralistic modes of action within the tumor microenvironment19. The compound 
was found to inhibit necroptosis, as well as IDO19, 89. Keto-indoles such as 1-(1H-Indol-2-
yl)-2-pyridin-3-yl-ethanone produced lower micromolar IC50 values than 1MDT but 
have yet to be selected for clinical investigation90. Currently 1MDT is the only 
tryptophan derivative to be utilized as an IDO inhibitor in a clinical trial91. Many IDO 
inhibitors utilize the Indole core due to the fact that the natural substrate incorporates this 
frame92, but lower IC50 values have been achieved through various screening methods 
and by utilizing different core molecules entirely93-99.  
 Quinone based IDO inhibitors are another class of small molecule inhibitors that 
achieve low micromolar IC50 values. The simple quinone, menadione inhibits IDO with a 
Ki value of 0.58 μM, a major improvement on the inhibitory activity of all the tryptophan 
derivatives100. Further derivatization of the quinone scaffold decreased the IC50 values of 
these inhibitors, but selectivity issues plague this genre of compounds reducing their 
efficacy as potent IDO inhibitors98, 101. Simple functionalization of quinones was 
investigated by multiple groups with varying success. The quinone scaffold alone does 
not impart strong binding affinity to the IDO active site. Aminophenoxazinone 
derivatives seemed promising due to the reactive amino functionality added to these 
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analogs, but in assays, these molecules produced only modest μM inhibition of IDO102.  
Imidazole and triazole cores have also been investigated with most reaching low 
micromolar inhibition constants96-98, 103, 104. Recently, researchers have isolated some 
natural product inhibitors of IDO from surprising sources101, 105, 106. Xestolactone A, 
derived from the sea sponge Xestospongia vansoesti work as a competitive inhibitor to 
the IDO binding site and has acute potency. The catechin, epigallocatechin-3-gallate, 
inhibits IDO function by disrupting STAT1 signaling and blocking expression of IDO. 
Multiple groups have explored naphthoquinone and pyranonaphthoquinone derivatives as 
potent IDO inhibitors107.Many of these derivatives utilize common functional groups and 
structural similarity to annulin B108. Annulin A and B were identified as natural product 
derived IDO inhibitors as early as 2009 and have activity on the nanomolar scale109. 
Pyranonaphthoquinone derivatives incorporating a carborane moiety were first 
introduced in 2014 with IC50 values as low as 0.78 μM110. Annulin A served as the parent 
molecule to a class of benzofuranquinone analogs. Though similar in structure to Annulin 
A, these derivatives exhibit surprisingly poor activity with IC50 values only reaching the 
millimolar range111. β-lapachone has been used in clinical trials as a cytoxic tumor 
targeting agent, but has recently been shown to be a potent IDO inhibitor as well107.  
 Other IDO inhibitors incorporating varying cores have recently been identified 
and studied in various cell lines and assays112. A group of phenyl benzene-
sulfonylhydrazides show high enzymatic affinity for IDO with IC50 values as low as 
61nm in enzymatic assays and similarly low (nM range) EC50 values in HeLa cells113. 
Bromophenylhydrazinyl benzenesulfonylphenylurea derivatives were synthesized and 
tested within a murine CT26 model and yielded up to 30% tumor weight reduction and 
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25% tumor growth reduction114. The antihypertensive agent candesartan cilexetil was 
also found to potently inhibit IDO. Though candesartan is the active portion of the drug, 
when administered alone, it’s inhibition activity was notably lower than that of 
candesartan cilexetil, indicating the entire structure plays a role in the inhibition of the 
active site115.  
Currently the most potent class of IDO inhibitors that have been studied in depth and 
utilized in clinical trials are the N-hydroxyamidine based inhibitors116. Using a high 
throughput screening process Incyte discovered the highly competitive inhibitor 4-amino-
1,2,5-oxadiazole-3-carboximidamide, and optimized the molecule into the 
pharmacophore Epacadostat (INCB024360)117-119.  
 Multiple groups have developed IDO targeting drugs that work in concert with 
other cancer drugs or DNA damaging agents. 1-methyl-D-tryptophan was conjugated to a 
platinum IV DNA damaging agent and was shown to have efficacy in cisplatin resistant 
cell lines120. The conjugate drug was more effective than solo therapy with either the 
DNA damage agent or the IDO inhibitor120. Platinum prodrugs have also been developed 
to target TDO, in an attempt to promote immune response within the tumor 
environment121.  
 Tumor derived hypoxia has also been targeted by researchers looking to more 
selectively target cancer. Nakashima and company developed hypoxia targeting agents 
coupled with 1-methyl tryptophan derivatives and observed increased efficacy within 
multiple cell lines due to a coupling of the cytoxic activity of the hypoxic agents followed 
by the metabolization of the drug into potent IDO inhibitors122.    
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1.7  IDO inhibition in the clinic 
 IDO inhibitors have routinely been tested in the clinic as a solo therapeutic, or in 
conjunction with or contrasted against PD1-PDL1 antibody inhibitors and/or various 
DNA damaging agents123. Table 1 summarizes the scope, drug combination, and target 
cancer type for most of the clinical trials investigating IDO inhibition. The three major 
small molecule inhibitors used in clinical trials are Indoximod, Epacadostat (incyte’s N-
hydroxyamidine inhibitor), and GDC-091998, 124. Epacadostat has been tested in multiple 
phase I and II trials in combination with CTLA-4 and PD-1/PD-L1 inhibitors124. 
Epacadostat has been shown to promote CD-8+ T cell and NK-cell proliferation and 
migration to the tumor milieu as well as suppress conversion of naïve T-cells into Treg 
cells117, 125, 126. GDC-0919 in combination with chemotherapy promotes an increase in 
complement deposition due to upregulation of vascular cell adhesion molecule-1 
(VCAM-1) on endothelial cells within the tumor127. It has also been investigated in 
combination therapy with the PD-L1 inhibitor atezolizumab128. GDC-0919 produced 
promising results in phase 1 trials with a high dosage tolerance but failed to effectively 
reduce tumor proliferation when used as single therapeutic124. Though incyte’s 
epacadostat passed phased I and II trials with promising results, the phase III trials of 
epacadostat in combination with EGFR and PD-1 monoclonal antibodies have failed, 
showing no increased benefit over the monoclonal antibodies as a single treatment. 
A few trials have also explored using IDO peptides or antibodies against IDO as a 
vaccine to promote immune response.  A phase I clinical vaccination trial 
(NCT01219348) tested the efficacy of an IDO-derived peptide with montanide adjuvant 
on stage III and IV non-small cell lung cancer (NSCLC) patients. The investigators found 
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that the vaccine led to a decrease in Treg cell count as well as a possible increase in NK 
cells129, 130 .  Currently, there no clinical trials investigating the an IDO inhibitor with a 
PARP (DNA repair protein) inhibitor or any other high profile immuno-regulatory target 
outside of the Immune checkpoint inhibitors (i.e. PD-1 or CTLA-4 targeting inhibitors). 
While patient response IDO inhibitor immunotherapy has been compared to DNA 
damaging agent- immune checkpoint inhibitor cocktails, the three have only been used 
together in a few early phase clinical trials and with a scope limited to dose safety 
determination. Though the list of viable IDO small molecule inhibitors is growing 
steadily with the use of high throughput screening and intelligent design, only the major 
three IDO inhibitors above have been investigated in phase III trials. This lack of 
diversity in pharmacophores has somewhat stalled discovery of novel treatment 
combinations, and allowed phase III failures of the most utilized drugs to cast doubt on 
the feasibility of IDO inhibition as an effective Immunotherapeutic target.   
1.8 DNA Repair Mechanisms as targets for Immunotherapy. 
DNA repair enzymes have recently become a promising target for new cancer 
treatments. These treatments often utilize small molecule inhibitors and/or antibodies to 
perturb normal cellular DNA repair. Poly (ADP-ribose) polymerase (PARP), in particular 
has been explored in the clinic with multiple inhibitors being approved for monotherapy 
against MMRD breast cancer cell lines. PARP is recruited to the site of DNA damage 
where it specifically repairs single strand breaks. Without normal function of PARP these 
SSB’s would lead to double strand breaks and stalled replication forks. The cell can still 
maintain genetic stability through other repair mechanisms such as homologous 
recombination or mismatch repair. In a method called synthetic lethality, PARP inhibitors 
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promote cell death only in cancer lines that are deficient in the back up repair 
mechanisms, while not having an effect on WT cells.  
Another DNA repair enzyme recently highlighted as a target for inhibition is DNA 
Polymerase gamma (POLγ). POLγ is critical to mitochondrial DNA replication and 
repair. Though few inhibitors have been developed specifically for POLγ inhibition, 
multiple known small molecules have shown inhibition activity against POLγ. Multiple 
different types of cancers hijack the mitochondria to help produce an environment primed 
for rapid cellular division. The POLγ inhibitor Menadione (Vitamin K3) has been shown 
to disrupt redox shuttling and homeostasis and increase production of ROS which can 
subsequently lead to cell death via apoptosis.  
 Clinical researchers have utilized these inhibitors in conjunction with other 
chemotherapy drugs to selectively target cancer cells. Though some have proven 
effective, most combination therapies have not seen widespread use or FDA approval for 
multiple types of cancers.   
1.9 Future Prospects and Experimental Aims 
With the recent high profile phase III failures of Incyte’s Epacadostat as well as other 
promising IDO small molecule inhibitors in late stage clinical trials, excitement over the 
possibilities of IDO inhibition has waned. These results do not prove that IDO is not a 
feasible or promising target but simply highlight a need for increased study into the 
feedback loops and induction of IDO within the tumor environment. Specifically, probes 
and methods are needed to delineate the downstream effects of IDO inhibition. IDO has 
been shown to experience an increase in expression due to inhibition of cellular IDO with 
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Indoximod, indicating the intended increase in inflammation due to suppressing IDO, in 
turn upregulates IDO. IDO also promotes and sustains function of PARP in the presence 
of PARP inhibitors37. While a host of studies have shown an increase in IDO expression 
in conjunction with overexpression of PD-1, attempts to combine IDO inhibitors with 
PD-1 specific monoclonal antibodies, does not increase overall survival rates of patients. 
This may be due to the fact that the tumor environment often utilizes multiple methods to 
exact the same immuno-suppressive environment, and inhibition of a single effector 
pathway can cause produce a heightened inflammation event that in turn activates other 
immune suppressive effector pathways that have been hijacked by the cancerous cells. 
The intricate and often obscure multifaceted suppression of the immune system by cancer 
cells can only elucidated by designing probes that exact multiple effects concurrently on 
the tumor environment.  
Cancer immunologists might explore the role of IDO in other inflammatory diseases such 
as Crohn’s disease or Diabetes for insight on ulterior functions of IDO. In other 
inflammatory diseases, IDO inhibition coupled with other treatments have produced 
beneficial results. Understanding how a blockade of IDO in other inflammation 
environments affects the immune system might provide critical insight on novel modes of 
action utilized by cancer cell when coopting IDO. 
The focus on simply inhibiting IDO function or combining this inhibition with immune 
checkpoint inhibitors might also be hindering progress in the development of potent 
immunotherapeutic agents. Since the expression of multiple immune suppressive 
pathways are governed by common upstream transcription events, a focus on blocking 
the transcription of immune suppressors in conjunction with active inhibition immune 
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checkpoints might be more effective. In a similar fashion to method of broad neutralizing 
antibodies using three or more determinants to target the viral envelope in HIV infection, 
cancer immunologists could increase the amount of concomitantly targeted effector 
pathways in addition to shifting the focus from direct inhibition to transcription or 
expression inhibition. Even in the face of recent setbacks, IDO remains a promising 
therapeutic target. With an in-depth investigation of regulatory feedback loops, coupled 
with new multi-target inhibition strategies, IDO immunotherapy could one day represent 
the pinnacle of chemical immunology research and clinical success.  
1.10 Experimental aims: Discovering the interplay between IDO and DNA Repair 
mechanisms 
IDO is critically involved in the de novo synthesis of NAD+ within the cell. The 
conversion of tryptophan into kynurenine through the kynurenine pathway directly ends 
with a final oxidation into NAD+. This process is increased in the event of INFγ 
mediated inflammation, since INFγ promotes upregulation of IDO and increases its 
activity. NAD+/NADH ratios are critical to mitochondrial function and energy 
production. As previously discussed, POLγ is a DNA repair enzyme specific to the 
mitochondria. Inhibiting POLγ has direct consequences on cellular energy production and 
mitochondrial stability. PARP, while not specific to the mitochondria, relies on cellular 
NAD+ to function properly with a recognizable depletion of NAD+ levels whenever 
increased PARP activity is observed. PARP function also promotes a metabolic shift in 
dependency from glycolysis to oxidative phosphorylation.  
On the surface, accumulation of DNA damage would theoretically promote immune 
recognition of cancer cells, especially if combined with inhibitors that block their 
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tolerogenic capabilities. Small molecule blockade of DNA damage repair (DDR) 
enzymes should increase antigen presentation and MHC expression on antigen presenting 
cells (APC), which would stimulate activation of cytoxic CD8 + T cells. Tumors often 
evade immunosurveillance by upregulating expression of immune checkpoint receptors 
such as CTLA-4 and PD-1/PDL-1 or through other immunomodulating enzymes like 
IDO. Currently CTLA-4 and PD-1/PDL-1 inhibitors are the main immunomodulatory 
inhibitors experiencing widespread use in the clinic. They have even seen success when 
combined with other DNA damaging agents or PARP inhibitors. While these effects have 
been promising, not all cancers are sensitized by PARP inhibition or contain genetic 
mutations that would make them particularly susceptible to immune checkpoint 
inhibitors. These inhibitors often have limited efficacy in a broad sense and are highly 
effective in a small subsection of cancers. Because of IDO’s ability to potentiate immune 
response through multiple methods, regardless of genetic mutation, it would be plausible 
that a conjugate IDO and DDR inhibitor would be a potent immunotherapeutic to a wide 
range of cancer cells.  
While the initial rationale is straightforward and could be explored in the clinic 
immediately, the underlying modes of action and synergies between these enzymes seem 
to depend on a few common metabolites and mechanisms that are not completely 
understood. Because IDO, PARP, and DNA POLγ are all critically involved in 
mitochondrial function and stability, we aimed to develop inhibitors that could also probe 
the interplay between the three enzymes. An in-depth analysis of these pathways with 
conjugate inhibitors, could lead to novel methods of immunotherapy that would 
specifically target cancer cells.  
21 
 
CHAPTER 2. MILD DEPROTECTION OF N-TERT‐BUTYLOXYCARBONYL (N-BOC) GROUP 
USING OXALYL CHLORIDE 
The contents of this chapter were previously published in RSC Advances.  
2.1 Rationale  
To explore the interplay between IDO and DNA POLγ, we aimed to develop a conjugate 
inhibitor of 1-MLT and Menadione (Figure 2.1). In the process of synthesizing FC1 we 
discovered a novel synthetic methodology for the deprotection of N-tert-butyloxycabonyl 
(N-BOC) group using oxalyl chloride. The (BOC) protected precursor was found to be 
unstable under classical TFA deprotections and would immediately hydrolyze and split 
into its precursor molecules upon addition of any TFA solution. The following chapter 
discusses the novel methodology and explores its applications across a broad spectrum of 










Figure 2.1 Conjugate inhibitor of IDO and POLγ (FC1) 
2.2 Introduction 
Synthetic organic transformations require the appropriate selection of reagents, catalysts, 
and most importantly, temporal masking and demasking agents. The objective for the 
deployment of relevant masking-demasking agents is to selectively form bonds of 
interest, whilst minimizing competing reactions with reactive functional groups. A good 
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protecting group will selectively block the functional group of interest, will be stable to 
the projected reactions, as well as being removed with readily available de-masking 
agents.131  
The amino group is a key functionality that is present in several compounds: natural 
products, amino acids and peptides.132 As such, there is an emergent need for its masking 
and demasking in forward synthesis. The tert‐butyloxycarbonyl (Boc) group is one of the 
classical masking functionalities employed in organic synthesis for the protection of 
amino groups.133-135 Boc fulfils this requirement of a ‘good’ protecting group, and is 
preferred in amino protection because of its stability to nucleophilic reagents, 
hydrogenolysis and base hydrolysis.136, 137 The Boc- masking group is installed by 
reacting the amino-substrate with di-tert-butyl dicarbonate under basic conditions138-140, 
or solvent free conditions141-143.  
  Traditional approaches for N-Boc deprotection relies largely on TFA-induced 
cleavage.144 Other strategies reported for the deprotection of N-Boc include the use of 
metal catalysts145, 146, as well as acetylchloride in methanol147, N-Boc removal with HCl 
in organic solvents: ethylacetate148 , dioxane149, in acetone.150 Other N-Boc deprotection 
methodologies include aqueous phosphoric acid151, 152, conc. sulfuric acid in 
tertbutylacetate133, boiling water153; silica gel has also been reported to effect the 
deprotection of N-Boc from thermally-sensitive heterocycles including heterocondensed 
pyrroles.154 Solvent free N-Boc deprotection strategies have been reported; Pal et al. 
reported the deprotection of several structurally diverse N-Boc substrates by using  
catalytic amounts of iodine.155 Aouf and co-workers have also reported the selective 
cleavage of N-Boc from N-Boc Chiral cyclosulfamides by fusion: mixing N-Boc 
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substrates with catalytic amounts of iodine under reduced pressure.156 Guillaumet and co-
workers have developed the basic deprotection of N-Boc substrates -  using sodium 
carbonate in refluxing DME.157 Similar basic N-Boc deprotection has been reported by 
Ewing et al., where sodium t-butoxide in slightly wet tetrahydrofuran was used to cleave 
off unactivated primary N-Boc from base stable substrates.158 Microwave assisted basic 
deprotection of secondary N-Boc substrates have been reported by Williams & 
Dandepally.159 Jia and co-workers have also developed a catalyst-free water-based 
deprotection of N-Boc aliphatic and aromatic substrates.160  
Most recently, several N-Boc deprotection schemes have been reported. These include N-
Boc deprotection  via thermolysis161, 162 and TMSI-mediated deprotection of N-Boc in 
zwiterrionic compounds163.  
In most cases, small molecules with sensitive functional groups or unique scaffolds are 
not compatible with these harsh deprotection conditions. Therefore, alternative reagents 
that orchestrate efficient deprotection, while providing functional group tolerance will be 
quintessential in the masking and unmasking of amines – a paradigm for broad utility.   
Oxalyl chloride is a highly accessible organic reagent that has many applications: from 
the routine synthesis of acid chlorides to the preparation of dihydroquinolines via a 
modified Bischler-Napieralski ring closure.164 The reactivity of oxalyl chloride with 
amides manifests in useful products through a typical imidoyl chloride intermediate when 
acetamide starting materials are used.165  
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2.3 Results and Discussion 
In our effort to generate an acylchloride from the C-terminus of a N-Boc protected 
peptidomimetic using oxalyl chloride, we observed the concomitant formation of the 
deprotected N-Boc to form the peptidomimetic with a free amine. We therefore set out to 
investigate if oxalyl chloride can mildly promote the deprotection of N-Boc substrates. 
Using 1-napthylamine as a model compound, we screened oxalyl chloride with a host of 
organic solvents at varying temperature conditions and equivalence. We found that the 
deprotection reaction proceeds poorly in neat oxalyl chloride. In addition, the reaction 
proceeds to access deprotected amino substrates in CHCl3 in moderate yields at room 
temperature over 24 – 48 h. However, under refluxing conditions in CHCl3, N-
chloroalkyl products formed, which were detected by GC-MS even after aqueous work-
up.  Further optimization led to the identification of a reaction condition that involved the 
use of five (5) equivalents of oxalyl chloride in methanol, which rapidly deprotects N-
Boc substrates with respectable yields (Table 1). Ultimately, the use of three (3) 
equivalents of oxalyl chloride in MeOH achieved good-to-excellent yields of deprotected 
tert-butyl carbamates. Here, we report a mild, and selective deprotection of tert-butyl 











TABLE 2.1: OPTIMIZATION OF DEPROTECTION USING N-BOC-1-NAPHTHYLAMINE-AMINE 
 
Entry Reaction conditions  Time 
(h) 
Yield (%)a 
1 oxalyl chloride, neat, 
RT 
72 0 
2 oxalyl chloride, 
CHCl3  
24 23b 
3 oxalyl chloride, 
CHCl3, 50°C   
24 12 
4 oxalyl chloride, 
CHCl3, 62°C   
24 0 
5 oxalyl chloride, 
MeOH, RT 
0.5 80 b 
Conditions: (a) (COCl)2 (1-3 equiv), (b) (COCl)2 (3 
equiv) 
 
The general deprotection scheme is shown in Scheme 1. We then applied this 
deprotection strategy to a variety of aromatic, aliphatic, and heterocyclic substrates. 
 

















R = alkyl, aryl, het.
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Table 2.1 illustrates the wide substrate scope of the oxalyl chloride-methanol 
deprotection strategy. It was effective against structurally diverse N-Boc amines; from 
aromatics, heterocyclic, aliphatics to alicyclic systems.  
Generally, the deprotection of N-Boc directly linked to aromatic moieties (Entry 1 - 9) 
were reasonably fast, occurring within 3 h and with high yields, >70%. Especially, 
compounds with electron withdrawing groups (EWG) including nitro, fluoro, chloro, 
iodo, or bromo display a faster response to the oxalyl chloride deprotection reagent with 
reactions in an hour.  
 
Table 2.2 Deprotection of structurally diverse N-Boc-amines 
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Table 2.2 (Cont.) Deprotection of structurally diverse N-Boc-amines 
Entry 









1.5  76 
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1.5  81 
9 
 






















Conceivably, electronic destabilization of the aryl carbamate induced by EWG promotes 
its cleavage by oxalyl chloride. We further observed that steric hindrance of methyl or 
isopropyl units attached to the aromatic ring and adjacent to the N-Boc group slows the 
reaction as seen for entries 2, 5, and 6.  Moreover, the deprotection reaction of 














































deprotection of aromatics by this deprotection strategy can be attributed to favorable 
electronic effects of these selected aromatic systems. The enhanced reactivity of the 
aromatic systems in contrast to their non-aromatic counterparts can be rationalized on the 
basis of the weakly nucleophilic oxygen atom of the carbonyl N-Boc atom. This oxygen 
is often stabilized or destabilized by the side group/chain directly connected to the N-Boc 
group. For entries possessing aromatics and electron-withdrawing groups, the 
pronounced ground-state destabilization of the carbonyl group caused by resonance or 
inductive effects, informs the increased O-atom reactivity to the electrophilic oxalyl 
chloride. This phenomenon could explain why the rate of reaction for alicyclic or 
heterocyclic systems were relatively slower.  
 
Scheme 2.2 Synthesis of 5 (FC1) via oxalyl chloride-mediated deprotection of 4 (EC1). 






































2. C5H5N, SiO2, RT, 2h
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A. Synthesis of N-Boc protected intermediate, 4
B. Traditional acid-mediated deprotection conditions of 4












Hybrid drugs possess multiple pharmacological activity166. These agents often have 
sensitive functional groups and their synthesis require protection and deprotection steps 
that are mild and of broad tolerance. One such molecule of interest in our laboratory is 5, 
which is a dual inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1) and DNA polymerase 
gamma.  
Hybrid drugs possess multiple pharmacological activity. These agents often have 
sensitive functional groups and their synthesis require protection and deprotection steps 
that are mild and of broad tolerance. One such molecule of interest in our laboratory is 5, 
which is a dual inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1) and DNA polymerase 
gamma. To demonstrate the versatility of this deprotection strategy, we used the N-Boc 
protected small-molecule precursor of 5, which possess acid-labile functionality. The 
synthesis of 4 was accomplished through, first, N-Boc protection of D-tryptophan, 1 and 
the subsequent N-methylation of the indole nitrogen to yield compound 2. Second, 
hydroxymenadione, 3 , was synthesized from a derivatized quinone and a Danishefsky 
diene. Third, amide coupling of D-methyl tryptophan and hydroxymenadione afforded 4 
in 10% yield.  Initial attempts to convert 4 to 5 using traditional acid-mediated protocols 
were unsuccessful. For example, experiments with (1 - 60%) TFA in DCM, and HCl in 
dioxane/methanol did not yield FC1. However, products corresponding to the cleavage of 
the ester bond in EC1 were observed.  We envisaged that the facile functional group 
tolerance of the described oxalyl chloride/MeOH methodology may work for our 
compound, 4. We therefore applied our deprotection methodology to 5. We observed a 
clean transformation of 4 to 5 (Scheme 2). Overall, oxalyl chloride is a worthy N-Boc 
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deprotection reagent for compounds with multiple functional groups and acid-labile 
groups. 
2.4 Determination of HCl effectiveness in Deprotection 
Considering that HCl/MeOH was incapable of deprotecting the N-Boc group in 4, we 
further explored the potential role of HCl to deepen our understanding of this reaction. 
One of the by-products of oxalyl chloride-alcohol reactions is the generation of HCl. 
Thus, the presumptive role of in-situ generated HCl in the deprotection of N-Boc 
substrates is reasonable. To examine this assertion, an equivalent mole of HCl generated 
in the oxalyl chloride-MeOH system was utilized in a model reaction as shown in Fig. 1. 
Specifically, N-Boc-L-Tryptophan was used as a model N-Boc amine. L-Tryptophan 
(0.657 mmol) in HCl (3.94 mmol) in MeOH, was compared to an equal mmol of N-Boc 
L-Tryptophan in oxalyl chloride (1.97 mmol) in MeOH system. After monitoring both 
reactions for 3 h, the N-Boc L-Tryptophan had been completely converted to L-
Tryptophan in the oxalyl chloride-MeOH system, whereas the HCl-methanol system did 
not yield an observable deprotection of the N-Boc-L-tryptophan substrate. This suggests 
that the deprotection of N-Boc in oxalyl chloride-MeOH system involves a broader 




Figure 2.1 Comparative reaction conditions for the deprotection of N-Boc-L-Tryptophan 





2.5 Proposed Mechanism 
In the course of the reaction of the oxalylchloride-mediated deprotection of model 
compound, tert-butyl N-(1-naphthyl)carbamate, the GC-products, isocyanate ester, II.The 
tert-butanol as well as the hydroxy-oxazolidinedione, IV (scheme 3a) were observed. 
 






































































































































A) Monitoring Oxalyl Chloride-facilitated deprotection of tert-butyl N-(1-naphthyl)carbamate












It is important to note that the isocynate II could be hydrolyzed back to the free 
amine during a water work up. In practice, the final product was observed only after 
aqueous workup, making this theory plausible. However, the mechanistic analysis was 
carried out prior to aqueous workup and therefore all other proposed intermediates could 
be formed due to side reactions or thermally instability during GCMS aquistion. 
We therefore propose a possible mechanism for the oxalyl chloride mediated 
deprotection of the N-Boc group (scheme 3b).  The electrophilic character of oxalyl 
chloride present opportunities for unique reactivity. In this context, addition reactions of 
the carbonyl unit of the carbamate with oxalyl chloride is plausible. Therefore, it is 
possible that the intermediate, 1, can be formed from such addition reactions. It has been 
shown that the oxalyl chloride mediated reactions with carboxylic acid derivates can 
yield isocyanate products .167, 168 Therefore, It is not far-fetched that the removal of 
tertbutanol, from intermediate, 3, yields the isocyanate ester intermediate , 4. The 
subsequent release of  tertbutyl ion from intermediate, 8 yields the oxazolidinedione-like 
intermediate, 9. It has been shown that the oxazolidinedione scaffold undergoes 
hydrolysis and ring opening to release carbon dioxide and related products.169, 170 It is 
therefore plausible that after the workup, the oxazolidinedione-like intermediate, 9 will 
undergo a ring opening and subsequently yield the amine product, 11, by releasing 
carbon dioxide, carbon monoxide and possible formyl side products. It must be noted that 
the tertbutyl cation side-product produced from the conversion of 8 to 9, will be 
transformed into isobutanol. This N-Boc deprotection methodology may have limited 





In a nutshell, we have developed a simple method for the deprotection of N-Boc group 
under the mild conditions of oxalyl chloride and methanol. Our methodology should 
prove useful in total synthesis; for the deprotection of N-Boc of substrates in the presence 
of other functional groups. Also, we have the strongest conviction that this study will 
serve as a model for the subsequent method development for the oxalyl chloride-
mediated direct transformation of N-Boc protected amines into amides.  
2.6 Experimental Procedures  
General procedure for N-Boc protection of amines 
In a 100 ml round bottom flask equipped with a stirring bar, the starting amine (500 mg) 
and TEA (or DIPEA) (3 equiv.) was dissolved in 2:1 v/v mixture of H2O/THF (45 ml) 
and allowed to stir at room temperature for 5 min. Once all starting materials were 
completely dissolved, the reaction mixture was cooled to 0 °C before di-tert-butyl 
dicarbonate (1.5 equiv.) was added to the solution in one portion. The reaction mixture 
was stirred at 0 °C for at least 2 h and then allowed to warm to room temperature over 4 
h. The reaction was monitored via TLC. Upon complete conversion to the N-Boc-
protected amine, THF was removed in vacuo and the crude material was subsequently 
extracted with dichloromethane (20 mL) , washed with deionized water twice (2 x 10 ml), 
and brine once (1 x 10 ml). The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated under low vacuum on a rotary evaporator. Most products did not require 
further purification to yield the pure protected amine. 
General procedure for the N-Boc deprotection: 
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 In a dry 25 ml round bottom flask equipped with a stirring bar, the starting 
material (50 mg) was dissolved in MeOH (3 mL) and allowed to stir at room temperature 
for 5 min.  Oxalyl chloride (3 equiv.) was then added to the solution (via syringe or 
micropipette) directly into the reaction solvent mixture. Sputtering and an increase in 
temperature of the reaction mixture were observed immediately upon addition of the 
oxalyl chloride. The reaction mixture was allowed to stir for up to 4 h depending on the 
starting material. The reaction was monitored via TLC. Upon complete conversion of the 
N-Boc-protected amine, deionized water (5 mL) was added to the flask slowly. The crude 
material was subsequently extracted with dichloromethane (5 mL) and washed with 
deionized water twice (2 x 5 ml). The organic layer was dried over anhydrous MgSO4, 
filtered, and concentrated under low vacuum on a rotary evaporator. Some products 
required further purification via flash column chromatography to yield the pure 
deprotected amine.  
 
Tert-butyl N-(2-isopropylphenyl)carbamate (Entry 1a) 
Prepared according to general N-Boc procedure. Product : red liquid (870 mg, 3.69 
mmol, 100%).  
1H NMR [CDCl3, 400MHz]: δ 7.62 (d, 1H, CH, J=7.6 Hz), δ 7.17 (dd, 1H, CH, J= 8, 1.6 
Hz), δ 7.11 (td, 1H, CH, J= 7.6, 1.2 Hz) δ 7.03 (td, 1H, CH, J= 7.6, 1.2 Hz), δ 6.22 (s, 
1H, NH), δ 2.91(sep, 1H, CH, J=6.8 Hz), δ 1.44 (s, 9H, (CH3)3), δ 1.17 (d, 6H, (CH3)2, 
J=6.8Hz). 13C NMR [CDCl3, 101 MHz]: δ 153.6, 139.1, 134.7, 126.3, 125.4, 124.7, 
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123.1, 80.3, 28.4, 27.7, 23.0. The spectral data of the compound 1a was consistent with 
the values reported in the literature.171 
2-isopropylaniline (Entry 1b) 
Prepared according to general deprotection procedure. Product: Pale-yellow liquid (40 
mg, 0.29 mmol, 70 %) 
1H NMR [CDCl3, 400MHz]: δ 7.14 (dd, 1H, CH, J=7.6, 1.6 Hz), δ 7.02 (td, 1H, CH, J= 
7.6, 1.2 Hz), δ 6.80 (td, 1H, CH, J= 7.6, 1.2 Hz), δ 6.71(dd, 1H, CH, J=7.6, 1.6 Hz), δ 
3.96 (s, 2H, NH2), δ 2.91(sep, 1H, CH, J=6.8 Hz), δ 1.25 (d, 6H, (CH3)2, J=6.8 Hz). 13C 
NMR [CDCl3, 101 MHz]: δ 142.6, 133.2, 126.5, 125.5, 119.5, 116.3, 27.7, 22.3. The 
spectral data of the compound 1b was consistent with the values reported in the 
literature.172  
tert-butyl N-(1-naphthyl)carbamate (Entry 2a) 
Prepared according to general N-Boc procedure. Product: off-white solid (849 mg, 3.49 
mmol, 100%)  
 
1H NMR [CDCl3, 400MHz]: δ 7.89 (m, 3H, CH), δ 7.66 (d, 1H, CH, J= 8 Hz), δ 7.52 (m, 
3H, CH), δ 6.93 (s, 1H, NH), δ 1.61 (s, 9H, (CH3)3). 13C NMR [CDCl3, 101 MHz]: δ 
153.6, 134.1, 133.0, 128.7 (2C), 126.0 (2C), 125.9, 125.8, 124.5, 120.5, 118.8 (2C), 80.7, 
28.4. Melting point: 95-97 °C. The spectral data of the compound 2a was consistent with 
the values reported in the literature.173 
Naphthylamine (Entry 2b) 
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Prepared according to general deprotection procedure. Product: Brown solid (51 mg, 0.35 
mmol, 87 %) 
1H NMR [CDCl3, 400MHz]: δ 7.92 (m, 1H, CH), δ 7.69 (m, 1H, CH), δ 7.36 (m, 2H, 
CH), δ 7.19 (d, 2H, CH, J=4.4 Hz), δ 6.77 (pen, 1H, CH, J=4.4 Hz),  δ 4.81 (s, 2H, NH2). 
13C NMR [CD3OD, 101 MHz]: δ 145.4, 137.0, 130.3 (2C), 128.4, 127.7, 123.6, 120.4, 
111.8(2C). Melting point: 49-52 °C. The spectral data of the compound 2b was consistent 
with the values reported in the literature.174 
 
tert-butyl N-(3-chlorophenyl)carbamate (Entry 3a) 
Prepared according to general N-Boc procedure. Product: White solid (892 mg, 3.9 
mmol, 100%) 
1H NMR [CDCl3, 400MHz]: δ 7.44 (singlet, 1H, CH), δ 7.09 (m, 2H, CH), δ 6.91 (dt, 
1H, CH, J= 7.2, 1.6 Hz), δ 6.48 (s, 1H, NH), δ 1.44 (s, 9H, (CH3)3). 13C NMR [CDCl3, 
101 MHz]: δ 152.5, 139.6, 134.7, 129.9, 123.0, 118.6, 116.5, 28.3. Melting point: 69-70 
°C. The spectral data of the compound 3a was consistent with the values reported in the 
literature.175 
 
3-chloroaniline (Entry 3b) 
Prepared according to general deprotection procedure. Product: Yellow liquid (46 mg, 
0.36 mmol, 83 %) 
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1H NMR [CDCl3, 400MHz]: δ 7.03 (t, 1H, CH, J= 8 Hz), δ 7.70 (ddd, 1H, CH, J= 8, 2, 
0.8 Hz), δ 6.91 (t, 1H, CH, J= 2 Hz), δ 6.50 (ddd, 1H, CH, J= 8, 2, 0.8 Hz),  δ 3.648 (s, 
2H, NH2). 13C NMR [CDCl3, 101 MHz]: δ 147.7, 134.9, 130.3, 118.5, 115.0, 113.2. The 
spectral data of the compound 3b was consistent with the values reported in the 
literature.176 
 
tert-butyl N-(3-chloro-4-fluorophenyl)carbamate (Entry 4a) 
Prepared according to general N-Boc procedure. Product: solid (843 mg, 3.4 mmol, 
100%) 
1H NMR [CDCl3, 400MHz]: δ 7.575 (dd, 1H, CH, J= 6.2, 2 Hz), δ 7.138 (ddd, 1H, CH, 
J= 8.8 , 4,  2.8 Hz), δ 7.047 (t, 1H, CH, J= 8.8 Hz), δ 6.554 (s, 1H, NH), δ 1.53 (s, 9H, 
(CH3)3) 13C NMR [CDCl3, 101 MHz]: δ 153.9, 136.4, 135.6, 131.5, 128.8, 79.7, 28.3, 
20.9, 18.2. Melting point:  130-132 °C. The spectral data of the compound 4a was 
consistent with the values reported in the literature.177 
 
3-chloro-4-flouroaniline (Entry 4b) 
Prepared according to general deprotection procedure. Product: solid (47 mg, 0.32 mmol, 
80%) 
1H NMR [CDCl3, 400MHz]: δ 6.91 (t, 1H, CH, J= 8.8 Hz), δ 6.68 (dd, 1H, CH, J= 6.4, 
2.8 Hz) δ 6.50 (ddd, 1H, CH, J= 8.8, 4, 2.8 Hz),  δ 3.48 (s, 2H, NH2). 13C NMR [CDCl3, 
101 MHz]: δ 152.8, 150.5, 143.2, 143.2, 121.1, 120.9, 116.9, 116.7, 116.4, 114.3, 114.2. 
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Melting point: 46-48 °C. The spectral data of the compound 4b was consistent with the 
values reported in the literature.178 
 
tert-butyl N-(2,4,6-trimethylphenyl)carbamate (Entry 5a) 
Prepared according to general N-Boc procedure. Product: Off-white solid (870 mg, 3.69 
mmol, 100%) 
1H NMR [CDCl3, 400MHz]: δ 6.91 (t, 1H, CH, J= 8.8 Hz), δ 6.68 (dd, 1H, CH, J= 6.4, 
2.8 Hz) δ 6.50 (ddd, 1H, CH, J= 8.8, 4, 2.8 Hz), δ 3.48 (s, 2H, NH2). 13C NMR [CDCl3, 
101 MHz]: δ 153.9, 136.4, 135.6 (2C), 128.8, 79.7, 28.3, 20.9, 18.2. The spectral data of 
the compound 5a was consistent with the values reported in the literature.179 
 
2,4,6-trimethylaniline (Entry 5b) 
Prepared according to general deprotection procedure. Product: Pale yellow liquid (47 
mg, 0.35 mmol, 83 %) 
1H NMR [CDCl3, 400MHz]: δ 6.63 (s, 2H, CH), δ 2.10 (s, 3H, CH3) δ 2.07 (s, 6H, 
CH3). 13C NMR [CD3OD, 101 MHz]: δ 142.3, 130.8, 129.5, 124.7, 21.7, 18.9. The 
spectral data of the compound 5b was consistent with the values reported in the 
literature.180 
 
tert-butyl N-(2,6-diisopropylphenyl)carbamate (Entry 6a) 
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Prepared according to general N-Boc procedure. Product: Pale red solid (782 mg, 2.82 
mmol, 100%) 
1H NMR [CDCl3, 400MHz]: δ 7.24 (t, 1H, CH, J=8 Hz), δ 7.107 (d, 1H, CH, J= 8 Hz), 
δ 5.82 (s, 1H, NH), δ 3.16 (s, 2H, 2(CH)), δ 1.505 (s, 9H, (CH3)3), δ 1.17 (d, 12H, 
2(CH3)2, J=6.8 Hz). 13C NMR [CDCl3, 101 MHz]: δ 153.9, 136.4, 135.6, 131.5, 128.8, 
79.7, 28.3, 20.9, 18.2. Melting point:  145-148 °C. The spectral data of the compound 6a 
was consistent with the values reported in the literature.181 
 
2,6-diisopropylaniline (Entry 6b) 
Prepared according to general deprotection procedure. Product: red liquid (49 mg, 0.28 
mmol, 78 %) 
1H NMR [CDCl3, 400MHz]: δ 7.06 (d, 2H, CH, J=8 Hz), δ 6.83 (t, 1H, CH, J= 7.6 Hz), 
δ 3.78 (s, 2H, NH2), δ 2.97 (sep, 2H, 2(CH), J= 6.8 Hz), δ 1.30 (d, 12H, 2(CH3)2, J=6.8 
Hz). 13C NMR [CDCl3, 101 MHz]: δ 140.2, 132.5, 122.8, 118.6, 28.0, 22.5, 21.9. The 
spectral data of the compound 6b was consistent with the values reported in the 
literature.182 
 
tert-butyl N-(4-nitrophenyl)carbamate (Entry 7a) 
Prepared according to general N-Boc procedure. Product: pale yellow solid (743.4 mg, 
3.12 mmol, 86.2%) 
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1H NMR [CDCl3, 400MHz]: δ 7.15 (d, 2H, CH, J = 8.6 Hz), 6.71 (d, 2H, CH, J = 8.9 
Hz), 1.48 (s, 9H, (CH3)3). 13C NMR [CDCl3, 101 MHz]: δ 153.4, 151.9, 131.2, 121.7, 
115.7, 80.4, 28.3. Melting point:  112-113 °C. The spectral data of the compound 7a was 
consistent with the values reported in the literature.183 
 
3-nitroaniline (Entry 7b) 
Prepared according to general deprotection procedure. Product: yellow solid (22 mg, 0.16 
mmol, 76 %) 
1H NMR [CD3OD, 400MHz]: δ 7.92 (d, 2H, CH, J = 9.1 Hz), 6.71 (d, 2H, CH, J = 9.1 
Hz). Melting point:  146-147 °C. The spectral data of the compound 7b was consistent 
with the values reported in the literature.184 
 
tert-butyl N-(3-bromo-4-fluorophenyl)carbamate (Entry 8a) 
Prepared according to general N-Boc procedure. Product: pale yellow solid (763 mg, 2.63 
mmol, 100%) 
1H NMR [CDCl3, 400MHz]: δ 7.72 (dd, 1H, CH, J=5.8, 2.8  Hz), δ 7.202 (ddd, 1H, CH, 
J= 8.8, 4, 2.8 Hz), δ 7.045 (t, 1H, CH, J= 8.8 Hz), δ 6.456 (s, 1H, CH), δ 1.534 (s, 9H, 
(CH3)3). 13C NMR [CDCl3, 101 MHz]: δ 156.3, 152.5, 135.3, 123.4, 118.9, 116.4, 
109.1, 81.1, 28.3.   
 
3-bromo-4-fluoroaniline (Entry 8b) 
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Prepared according to general deprotection procedure. Product: Brown liquid (57 mg, 
0.30 mmol, 88 %) 
1H NMR [CDCl3, 400MHz]: δ 6.89 (t, 1H, CH, J= 8.8 Hz), δ 6.84 (dd, 1H, CH, J= 5.6, 
2.8 Hz) δ 6.54 (ddd, 1H, CH, J= 8.8, 4, 2.8 Hz),  δ 3.57 (s, 2H, NH2). 13C NMR [CDCl3, 
101 MHz]: δ 13C NMR (101 MHz, CDCl3) δ 154.2, 151.8, 143.8, 119.5, 117.1, 115.4, 
109.5. The spectral data of the compound 8b was consistent with the values reported in 
the literature.185 
 
tert-Butyl (4-iodophenyl)carbamate (Entry 9a) 
Prepared according to general N-Boc procedure. Product: off-white solid (710.2mg, 2.22 
mmol, 97.5 %) 
1H NMR [CDCl3, 400MHz]: δ 7.56 (s, 1H), 7.54 (s, 1H), 7.12 (d, J = 8.7 Hz, 2H), 6.44 
(s, 1H), 1.49 (d, J = 0.6 Hz, 9H). 13C NMR [CDCl3, 101 MHz]:  δ 152.5, 138.2, 120.4, 
85.7, 80.9, 30.9, 28.3. The spectral data of the compound 9a was consistent with the 
values reported in the literature.186 Melting point:  143.7-147 °C 
 
4-Iodoaniline (Entry 9b) 
Prepared according to general deprotection procedure. Product brown solid: (29.5 mg, 
0.13 mmol, 86 %) 
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1H NMR [CDCl3, 400MHz]: δ 7.63 (d, J = 7.3 Hz, 2H), 6.71 (d, J = 7.4 Hz, 2H), 4.21 (s, 
2H). Melting point:  67-68 °C. The spectral data of the compound 9b was consistent with 
the values reported in the literature.187 
 
tert-butyl N-(N-(2-Methoxyphenyl)piperazine)carbamate (Entry 10a) 
Prepared according to general N-Boc protection procedure. Product: White solid (760 
mg, 2.6 mmol, 100%) 
1H NMR [CDCl3, 400MHz]: δ 7.11 (t, 1H, CH, J=7.4 Hz), δ 6.93 (m, 2H, CH), δ 3.90 
(s, 3H, CH3), δ 3.72 (s, 4H, (CH2)2), δ 3.15 (s, 4H, (CH2)2),δ 1.50 (s, 9H, (CH3)3,). 13C 
NMR [CDCl3, 400 MHz]: δ 154.7 (2C), 152.3, 121.3 (2C), 111.8 (2C), 79.9, 55.5, 50.9, 
28.4. Melting point:  68-69 °C. The spectral data of the compound 10b was consistent 
with the values reported in the literature.188 
 
N-(2-Methoxyphenyl)piperazine (Entry 10b) 
Prepared according to general deprotection procedure. Product: (42 mg, 0.21 mmol, 64 
%) 
1H NMR [CDCl3, 400MHz]: δ 6.89 (m, 1H, CH), δ 6.83 (m, 2H, CH) δ 6.77 (m, 1H, 
CH), δ 3.57 (s, 3H, CH3), δ 2.94 (m, 8H, 4(CH2)). 13C NMR [CDCl3, 101 MHz]: δ 
152.3, 141.8, 122.9, 121.0, 118.2, 111.4, 55.3, 52.0, 46.3.  Melting point:  37-40 °C. The 





tert-butyl N-(N-(4-thiophene-phenyl)piperazine)carbamate (Entry 11a)  
Prepared according to general N-Boc procedure. Yield: (704 mg, 2.04 mmol, 100%) 
1H NMR [CDCl3, 400MHz]: δ 7.52 (d, 2H, CH, J= 8.8Hz), δ 7.18 (d, 2H, CH, J= 4.4 
Hz), δ 7.04 (m, 1H, CH),  δ 6.92 (d, 2H, CH, J= 9.2 Hz), δ 3.58 (t, 4H, CH2, J= 5.2 Hz), δ 
3.16 (t, 4H, CH2, J= 5.2 Hz), δ 1.49 (s, 9H, (CH3)3,).   13C NMR [CD3OD, 101 MHz]:  
154.7, 150.5, 144.5, 127.9, 126.9, 126.4, 123.6, 121.8, 116.5, 79.9, 49.1, 28.4. 
 
N-(4-thiophene-phenyl)piperazine  (Entry 11b) 
Prepared according to general deprotection procedure. Product: off-white solid (61 mg, 
0.25mmol, 87 %) 
1H NMR [CDCl3, 400MHz]: δ 7.54 (d, 2H, CH, J= 9.2 Hz), δ 7.27 (m, 2H, CH) δ 7.02 
(m, 3H, CH), δ 3.44 (m, 4H, CH2), δ 3.38 (m, 4H, CH2). 13C NMR [CD3OD, 101 MHz]: 
δ 149.7, 143.9, 128.8, 126.7, 124.6, 122.6, 116.6, 45.7, 43.0 
tert-butyl N-(cyclohexyl)carbamate (Entry 12a) 
Prepared according to general procedure. Product: colourless solid (1.0 g, 5.04 mmol, 
100 %) 
1H NMR [CDCl3, 400MHz]: δ 4.41 (s, 1H, CH), δ 3.43 (s, 1H, NH), δ 1.92 (m, 2H, 
CH), δ 1.69 (m, 3H, CH),  δ 1.46 (s, 9H, (CH3)3,)δ 1.36 (m, 2H, CH2), δ 1.12 (m, 3H, 
CH). Melting point:  79-80 °C. The spectral data of the compound 12a was consistent 




Cyclohexylamine (Entry 12b) 
Prepared according to general deprotection procedure. Product: colourless liquid (27 mg, 
0.28 mmol, 55 %) 
1H NMR [CDCl3, 400MHz]: δ 2.63 (s, 1H, CH), δ 1.93 (m, 2H, CH2,), δ 1.70 (m, 3H, 
CH), δ 1.58 (d, 1H, CH, J= 12.4 Hz), δ 1.26 (q, 2H, CH2, J=12.4 Hz), δ 1.11 (p, 3H, CH, 
J=12.4 Hz). The spectral data of the compound 12b was consistent with the values 
reported in the literature.191 
 
tert-butyl N-(2-[2-(2-aminoethoxy)ethoxy]ethanamine)carbamate (Entry 13a) 
Prepared according to general procedure. Product: pale yellow liquid (318 mg, 1.2 mmol, 
38 %) 
1H NMR [CDCl3, 400MHz]: δ 4.13 (s, 1H, CH), δ 3.48 (s, 3H, CH), δ 3.41 (s, 3H, CH), 
δ 3.18 (s, 2H, CH2), δ 2.74 (s, 1H, CH), δ 1.78 (s, 1H, CH2),   δ 1.31 (s, 9H, (CH3)3,). 
The spectral data of the compound 13a was consistent with the values reported in the 
literature.192 
 
2-[2-(2-aminoethoxy)ethoxy]ethanamine (Entry 13b) 




1H NMR [CDCl3, 400MHz]: δ 3.84 (m, 4H, CH2), δ 3.73 (t, 2H, CH2, J= 5.0 Hz), δ 3.70 
(d, 2H, CH2, J= 1.2 Hz), δ 3.64 (s, 1H, CH), δ 3.32 (d, 1H, CH, J= 1.6 Hz), δ 3.14 (t, 2H, 
CH2, J=4.6 Hz). The spectral data of the compound 13b was consistent with the values 
reported in the literature.193 
 
EC1  
1-methyl tryptophan was protected prior to synthesis of the conjugate molecule. Prepared 
according to general procedure. 
1H NMR [(CD3)2CO , 400MHz]: δ 8.06 (d, 1H, CH, J= 8.4 Hz), δ 7.65 (d, 1H, CH, J= 8 
Hz), δ 7.55 (d, 1H, CH2, J= 2.4 Hz), δ 7.38 (m, 2H, CH), δ 7.20 (m, 2H, CH), δ 7.07 (m, 
1H, CH), δ 6.91 (s, 1H, CH), δ 4.73 (m, 1H, CH), δ 3.83 (s, 3H, CH3), δ 3.77 (s, 1H, 
NH), δ 3.42 (m, 2H, CH2), δ 2.16 (s, 3H, CH3), δ 1.43 (s, 9H, (CH3)3). 13C NMR 
[(CD3)2CO , 101MHz]: δ 184.1, 183.6, 170.7, 155.6, 155.0, 148.4, 137.3, 135.3, 133.9, 










CHAPTER 3. SYNTHESIS OF SMALL MOLECULE INHIBITORS FOR NOVEL IMMUNOTHERAPY 
TREATMENTS 
3.1 Introduction 
Synthetic lethality has been utilized as an effective treatment to target mismatch repair 
deficient (MMRD) cancer cells. This perturbation of the stressed repair systems has not 
to our knowledge, previously been combined with inhibition of IDO. PARP and IDO 
both modulate cellular NAD/NADH ratios. PARP requires an abundance of NAD+ to 
function properly while IDO activation indirectly potentiates cellular NAD+ levels 
through the kynurenine pathway194, 195. Induction of IDO initially increases NAD+ 
synthesis but also has been shown to increase NAD+ catabolism196. IDO inhibitors have 
achieved limited success in the clinic when combined with other small molecule or 
antibody modulators of the immune response, but there have been very few studies 
probing the effect on of IDO inhibition on DNA damage repair197. We therefore aimed to 
synthesize conjugate inhibitors of 1-methyl -L-tryptophan (1-MLT) or INCB14943 (a 
potent IDO inhibitor), and Olaparib (a PARP inhibitor).  
We also aimed to synthesize a small molecule probe to examine the effects of modulating 
redox homeostasis while concurrently inhibiting DNA repair mechanisms. Menadione, an 
analog of vitamin K, has been shown to trigger cell death by increasing the production of 
ROS. It is also known that menadione induced ROS promote the phosphorylation and 
subsequent activation of transducer kinases critical to DNA repair. The combination of an 
increase in ROS with the inhibition of PARP might increase PARPi effectiveness in 
MMRD cells and could help uncover new methods to target cancer cells that are highly 
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resistant to conventional chemotherapy. Menadione is has also been shown to inhibit 


























Figure 3.1 Target Inhibitors of IDO, DNA Polymerase γ, and PARP 
 
3.2 Synthetic Methodology  
1-MLT was synthesized by first BOC-protecting the free amine. The methylation of the 
indole amine was accomplished using the milder methylating agent dimethylcarbonate. 
The classical methylation utilizing methyl iodide could not be used because it was not 
selective for the indole position and produced multiple side products. 1-MLT(BOC) (3) 
was also synthesized by simply buying the methylated tryptophan and subsequently 
BOC-protecting the free amine. Olaparib was not used in it’s complete form, but the core 
of the PARP inhibitor was retained in the PARPi  analog compound (4). The PARPi (4) 
molecule would allow for direct coupling to the 1-MLT IDO inhibitor, but the conjugate 
would be an amide linker molecule, making it less likely to dissociate within the cell. The 
PARPi was therefore also converted into linker molecule (5) in order to form an ester 
version of the conjugate. Both final protected conjugates (6) and (7) were formed using 
an HATU coupling reaction from their necessary starting materials as shown in scheme 
3.1. The final conjugates (8) FC2 & (9) FC3 were the only compounds used in 


































































































3 5  
Scheme 3.1 Synthesis of IDO-PARP conjugate inhibitor molecules 
 
A) (BOC)2O, Na2CO3, H2O, 0 °C, 12 h.  B) DMC, TBAB, KOH, DMF, reflux, 3 h. C) 




























































9 (FC3)  
Scheme 3.1 (Cont.)  Synthesis of IDO-PARP conjugate inhibitor molecules 
E) 50% TFA, CH2Cl2, RT, 4 h. 
 
The menadione inhibitor offered few sites favorable for functionalization in its current 
form, so the hydroxymenadione (10) version was synthesized using a diels alder reaction 
of Danishefsky's diene with 2-Bromo-5-methyl-1,4-benzoquinone. A second analog of the 
Menadione molecule was synthesized via allylic bromination of the methyl group. The 
menadione analog containing the primary bromine (12) could undergo a facile SN2 
substitution with the PARPi linker (5) to produce the final conjugate (14). The PARPi (4) 
was combined with succinic anhydride in a ring opening amidation that would yield a new 
linker molecule capped with a free carboxylic acid (13). The carboxylic acid linker 
molecule was then coupled to the initial hydroxymenadione (10) via an EDC mediated 


















































































Scheme 3.2 Synthesis of POLγ-PARP conjugate inhibitor molecules 
 
A) Pyridine, CH2Cl2, 0 °C, 8 h.  B) NBS, hν, ACN, RT, 2-4 h. C) BrEtOH, Na2CO3, 
ACN, reflux, 2 h. D) Succinic Anhydride, DIPEA, DMF, reflux, 12 h, E) Na2CO3, 
ACN, reflux, 2 h, F) EDC, DMAP, CH2Cl2, 0 °C - RT, 24 h. 
 
The hydroxyamidne INCB14943 molecule was synthesized using a 3 step process. The 
first reaction of malononitrile with sodium nitrate and hydroxylamine afforded the 
hydroxyamidine (14). Compound 14 was then converted into the imidoyl chloride (15), 


























Scheme 3.3 Synthesis of INCB14943 
 
A) NaNH2, NH2OH(HCl),H2O, 0 °C- 50 °C, 6 h, 10N NaOH;  B) HCl, RT, 3 h; C) 4-
fluoro-3-bromoaniline, TEA, CH2Cl2, RT, 3 h.  
 
3.3 Future Directions 
Conjugates 12 and 13 were never purified to above 95 % purity in quantitative amounts 
to be utilized in biological assays. The synthesis of molecules containing the 
hydroxymenadione scaffold were prone to hydrolysis once coupled as an ester due to the 
high electron density of the molecule. These conjugate molecules often split during 
purification due to the fairly acidic nature of silica. Alumina columns did not provide the 
necessary separation of the final conjugate from side products. C18  based columns were 
particularly useful in separating the menadione conjugates but poor yields in the coupling 
reactions made it difficult to even begin purification.  
INCB14943 was never coupled to PARPi (11) as planned but would have theoretically 
offered the same effect as conjugate (6) or (7) with only a possible increase in inhibitory 
activity due to its potent activity as a single agent.  
Though these compounds were never fully tested in vitro, they offer fascinating targets 
for delineating the synergy between redox homeostasis and DNA repair mechanisms. 
Initially , docking experiments were planned to discover novel POLγ inhibitors that could 
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be coupled to PARP inhibitors or IDO inhibitors. It would also be useful to couple more 
potent redox active molecules to IDO inhibitors. Metal complex molecules that perturb 
mitochondrial function conjugated with IDO inhibitors would offer clear insight into 
signaling pathways and immune response due to oxidative stress. 
3.4 Experimental Procedures:   
BOC-Tryptophan (2) 
 4 g of Tryptophan and 3 eq of DIPEA or Na2CO3 was added to a dry 250 ml RBF 
equipped with a stir bar and dissolved in 75 ml of of a 2:1 H20/THF solution (v/v). The 
reaction mixture was cooled to 0 °C and stirred for 15 min. 1.2 eq of  (BOC)2O was 
charged into the flask and the mixture was stirred at 0 °C for 6 h. The reaction mixture 
was monitored via TLC. After reaction completion, the reaction mixture was 
concentrated via rotary evaporator until all THF had been removed. The crude material 
was then extracted with DCM, washed with 2 ml of 0.2 N HCl followed by brine, then 
dried over Na2SO4. The solution was filtered and solvent removed in vacuo to afford the 
pure product. No further purification was necessary. White Powder. 100% yield. 
1H NMR [CDCl3, 400MHz]: δ 10.04 (s, 1H, CH,), δ 7.27 (m, 2H, CH) δ 7.02 (m, 3H, 
CH), δ 3.44 (m, 4H, CH2), δ 3.38 (m, 4H, CH2). 13C NMR [CD3OD, 101 MHz]: δ 149.7, 
143.9, 128.8, 126.7, 124.6, 122.6, 116.6, 45.7, 43.0 
 
BOC-1-MLT (3) 
1 gram of BOC-TRP (2), 0.5 g of base (K2CO3/KOH/NaOH), 2 mL of dimethyl 
carbonate, 8 mL of dimethylformamide (DMF), and 0.2 g of catalyst (TBAB) were mixed 
together and heated to reflux. The reaction was monitored, and the products were 
identified by HPLC. The reaction (a mixture of N-methylated and N-,C-dimethylated 
products) was quenched by cooling the reaction mixture to room temperature and adding 
16 mL of water. Then an extraction was carried out with 20 mL of EtOAc which was 
washed twice with 20 mL of water. EtOAc was concentrated under vacuum to about 5 
mL. The resulting mixture was cooled and precipitated via slow addition of hexane. The 
suspension was filtered, washed with 50 mL of cold hexane, and dried under vacuum. 
The N-methylated product was isolated via flash column with a 25/75 (v/v) 
EtOAc/Hexane eluting solvent. Tan powder, 30% yield.  
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1H NMR [CDCl3, 400MHz]: δ 10.09 (s, 1H, OH), δ 7.59 (d, 1H, CH, J=  Hz), δ 7.40 (d, 
1H, CH, J= 7.6, 1.2 Hz), δ 7.22 (s, 1H, CH, J=7.6, 1.6 Hz), δ 7.08 (dt, 2H, CH , J=  Hz), 
δ 5.99 (d, 1H, CH, J=Hz), δ 4.49 (d, 1H, CH), δ 3.67 (d, 1H, CH), δ 3.27 (d, 1H, CH),  δ 
1.38 (s, 9H, (CH3)3,) 
PARPi-Linker 1 (5) 
500 mg of PARPi (4) was added to a dry 50 ml RBF equipped with a stir bar and 
dissolved in 10 ml of ACN. 2 eq of DIPEA was added to the reaction vessel and the 
mixture was heated to a mild reflux. 1.2 eq of 2-Bromoethanol was then charged into the 
flask and the mixture was refluxed vigorously at 100 °C for 2 hours. Upon completion of 
the reaction the ACN was completely removed and the crude material was dissolved in 
DCM and washed with 5, 5 ml DI H2O. The product was isolated via flash column with a 
7:93 (v/v) MeOH/DCM eluting solvent. White powder, 30 % yield. 
1H NMR [CDCl3, 400MHz]: δ 11.52 (s, 1H, NH), δ 8.43 (s, 1H, CH), δ 7.75 (m, 3H, 
CH), δ 7.28 (m, 2H, CH), δ 7.00 (m, 1H, CH),  δ 4.28 (s, 2H, CH2), δ 3.8 (m, 2H, CH2), δ 
3.64 (m, 2H, CH2), δ 3.31 (m, 2H, CH2), δ 3.02 (s, 2H, CH2),  δ 2.59 (s, 2H, CH2), δ 2.44 
(s, 2H, CH2).  
FC2-BOC (6) 
420 mg of 1MLT(BOC), 1.2 eq PARPi (4), 2 eq of HATU and 3 eq of DIPEA. were 
added to a dry 50 ml rbf equipped with a stir bar and dried under vacuum for 30 min. The 
reagents were dissolved in 3 ml of DMF and the reaction mixture was allowed to stir at 
RT for 24-48 hours. Ice water was added to the reaction was to the reaction mixture and a 
white solid precipitate formed. The suspension was centrifuged and the solvent was 
decanted, revealing the crude product. The organic product washed with water and 
centrifuged 2 more times before being extracted with DCM. The product was isolated via 
flash column with a 100% EtOAc eluting solvent.. Pink powder, 43 % yield. 
1H NMR [CDCl3, 400MHz]: δ 11.77 (s, 1H, NH), δ 8.34 (d, 1H, CH, J= 9.2 Hz), δ 7.83 
(m, 4H, CH), δ 7.08 (m, 4H, CH), δ 6.13 (m, 3H, CH), δ 6.12 (s, 1H, NH),  δ 4.35 (s, 2H, 
CH2), δ 3.97 (m, 1H, CH), δ 3.77 (s, 3H, CH3), δ 3.4 (m, 8H, CH), δ 2.74 (s, 2H, CH3), δ 




400 mg of 1MLT(BOC), 1.2 eq PARPiL1 (5), 2 eq of HATU and 3 eq of DIPEA. were 
added to a dry 50 ml rbf equipped with a stir bar and dried under vacuum for 30 min. The 
reagents were dissolved in 3 ml of DMF and the reaction mixture was allowed to stir at 
RT for 24-48 hours. Ice water was added to the reaction was to the reaction mixture and a 
white solid precipitate formed. The suspension was centrifuged, and the solvent was 
decanted, revealing the crude product. The organic product washed with water and 
centrifuged 2 more times before being extracted with DCM. The product was isolated via 
flash column with a 7:93 (v/v) MeOH/DCM eluting solvent. Tan powder, 21 % yield. 
1H NMR [CDCl3, 400MHz]: δ 8.63 (s, 1H, CH), δ 8.30 (m, 2H, CH), δ 7.78 (m, 4H, 
CH), δ 7.27 (m, 4H, CH),  δ 6.94 (m, 1H, CH), δ 4.70 (s, 2H, CH2), δ 4.28 (m, 2H, CH2), 
δ 3.54 (s, 2H, CH2), δ 3.38 (s, 1H, CH), δ 3.33 (s, 3H, CH3), δ 3.11 (m, 2H, CH2), δ 3.54 
(m, 6H, CH2), δ 1.39 (s, 9H, CH3). 
General BOC Deprotection Procedure 
100 mg of BOC -protected compound was placed in a 20 ml scintillation vial equipped 
with a stir bar. 50 % TFA in DCM was added to the reaction vessel and the reaction 
mixture was allowed to stir at RT for 2 hours. The reaction mixture was concentrated in 
vacuo to afford the crude TFA salt. The salt was converted to the free amine with 2 M 
NaOH and was extracted with EtOAc.  
FC2 (8) 
Prepared according to general deprotection procedure. Product: Pink powder, 43 % yield. 
1H NMR [CDCl3, 400MHz]: δ 8.35 (d, 1H, CH, J= 8.2 Hz), δ 7.86 (m, 3H, CH), δ 7.51 
(m, 3H, CH),  δ 7.09 (m, 4H, CH), δ 4.35 (s, 2H, CH2), δ 3.79 (s, 1H, CH), δ 3.75 (s, 3H, 
CH3), δ 3.28 (bm, 8H, CH), δ 2.73 (s, 2H, CH2).  
FC3 (9) 
Prepared according to general deprotection procedure. Product: Pink powder, 43 % yield. 
1H NMR [CDCl3, 400MHz]: δ 8.63 (s, 1H, CH), δ 8.30 (m, 2H, CH), δ 7.78 (m, 4H, 
CH), δ 7.27 (m, 4H, CH),  δ 6.94 (m, 1H, CH), δ 4.70 (s, 2H, CH2), δ 4.28 (m, 2H, CH2), 
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δ 3.54 (s, 2H, CH2), δ 3.38 (s, 1H, CH), δ 3.33 (s, 3H, CH3), δ 3.11 (m, 2H, CH2), δ 3.54 
(m, 6H, CH2).    
2-methyl-7-hydroxy-1,4- naphthoquinone (10) 
4-bromo-1-methylbenzoquinone was added to a dry 25 ml rbf, equipped with a stir bar, 
and dissolved in 10 ml of DCM. The flask was flushed with nitrogen and wrapped with 
foil before being cooled to 0 C. The diene was then added dropwise to the solution and 
the reaction mixture was allowed to warm to RT over 2 hours. 1.5 eq of Pyridine was 
then added to the reaction flask and the reaction mixture was allowed to stir for another 6 
h. The crude residue was concentrated in vacuo and then dissolved in 15 ml of DCM. 3 
ml of 2 M HCL was added to the solution and the organic layer was washed with 3, 10 ml 
portions of DI H2O before being dried over MgSO4.  The pure product was isolated via 
flash column with a 33:66 (v/v) EtOAc/toluene eluting solvent. Tan powder, 21 % yield. 
1H NMR [CDCl3, 400MHz]: δ 9.65 (s, 1H, OH), δ 7.97 (d, 1H, CH), δ 7.41 (d, 1H, CH), 
δ 7.23 (dd, 1H, CH), δ 6.83 (s, 1H, CH), δ 2.15 (s, 3H, CH). 
 (Bromo)-2-methyl- 1,4-naphthoquinone (12) 
500 mg of menadione was added to a dry rbf equipped with a stir bar and dissolved in 12 
ml of ACN. The starting material was cooled to 0 °C and 1.2 eq of NBS (dissolved in 4 
ml of ACN) was added to the stirring mixture dropwise. The reaction flask was wrapped 
with foil and exposed to uv light for 2 h. The crude material was isolated via rotary 
evaporation. The pure product was isolated via flash column with a 30/70 (v/v) 
EtOAc/Hexane eluting solvent. Yellow powder, 30% yield.  
1H NMR [CDCl3, 400MHz]: δ 8.05 (s, 1H, CH), δ 7.77 (m, 1H, CH) δ 6.83 (m, 2H, 
CH),  δ 2.45 (s, 2H, CH2). 
PARPiL2 (13) 
500 mg of PARPi and 1.2 eq of Succinic Anhydride was added to a dry 100 ml RBF 
equipped with a stir bar and dissolved in 30 ml of DMF. 2 eq of  DIPEA was charged into 
the flask and the mixture was stirred at 100 °C for 24 h. The crude material was extracted 
with DCM and washed with 2, 2 ml portions of 2 N HCL and then with DI H2O. The 
crude material was purified via column chromatography with a 3.5% MeOH/DCM 
eluting solvent. 94% Yield (600 mg). Produced a yellow powder  
1H NMR [CDCl3, 400MHz]: δ 11.52 (s, 1H, NH), δ 8.43 (s, 1H, CH), δ 7.75 (m, 3H, 
CH), δ 7.28 (m, 2H, CH), δ 7.00 (m, 1H, CH),  δ 4.28 (s, 2H, CH2), δ 3.8 (m, 2H, CH2), δ 
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3.64 (m, 2H, CH2), δ 3.31 (m, 2H, CH2), δ 3.02 (s, 2H, CH2),  δ 2.85 (m, 2H, CH2), δ 
2.75 (m, 2H, CH2).  
FC4 (14) 
500 mg of PARPiL1 (5) was added to a dry 50 ml RBF equipped with a stir bar and 
dissolved in 10 ml of ACN. 2 eq of DIPEA was added to the reaction vessel and the 
mixture was heated to a mild reflux. 1.2 eq of (Bromo)-2-methyl- 1,4-naphthoquinone 
(12) was then charged into the flask and the mixture was refluxed vigorously at 100 °C 
for 6 hours. Upon completion of the reaction the ACN was completely removed and the 
crude material was dissolved in DCM and washed with 2, 5 ml DI H2O. The product was 
isolated via flash column with a 5:95 (v/v) MeOH/DCM eluting solvent. White powder 
FC5 (15) 
100 mg of Hydroxymendadione (10) and 1.2 eq of PARPiL2 (13) was added to a dry 100 
ml RBF equipped with a stir bar and dissolved in 10 ml of ACN. 0.01 eq of  DMAP  and 
2 eq of EDC.HCl was charged into the flask simultaneously and the mixture was stirred 
at 0 °C for 2 h and then at RT for 12 h. The crude material was extracted with DCM and 
washed with 3, 5 ml portions of DI H2O. Product was purified using flash column 











CHAPTER 4. CELLULAR ANALYSIS OF SMALL MOLECULE PARP-IDO INHIBITORS  
4.1 Introduction 
As previously discussed, PARP and IDO are both commonly coopted by cancer cells to 
promote unchecked cell growth within the tumor microenvironment. The downstream 
metabolites and effector pathways of both enzymes are intertwined in ways that have not 
been thoroughly investigated. The conjugate inhibitors synthesized in chapter 3 were 
designed to target cells that over express one or both of the target enzymes. The selected 
cell lines were chosen by whether they had germline mutations to either BRC1 or BRC2, 
or if they endogenously expressed IDO. Within the tumor microenvironment, cancer cells 
themselves can express IDO upon stimulation by INFγ. or by mutations that cause 
constitutive expression. By synthesizing conjugate inhibitors that could target these cells, 
we aimed to highlight novel and synergistic effector pathways between the two enzymes.  
4.2 Results and Discussion 
The efficacy of FC2 and FC3 was first tested in MDA-MB-231, metastatic TNBC cells 
without germline BRCA mutations. After a 72 hour treatment with variable treatment 
concentrations, our data showed that FC2, the amide coupled conjugate had stronger 
inhibitory activity than the ester coupled conjugate. The IC50 values for both the FC2 







Figure 4.1 Cytoxic efficacy of conjugate inhibitors on cell viability of MDA-MB-231  
 
The conjugate inhibitors were then tested in HCC-1937, a metastatic TNBC cell line with 
a germline BRCA1 mutation at nt5832insC. HCC-1937 endogenously expresses PARP 
and is particularly susceptible to monotherapy treatment of Olaparib with an IC50 of ~ 12 
µM in literature. Upon 72 hour treatment with our conjugate inhibitors we obtained IC50 
values of 3.63 µM ± 0.12 and 5.97 µM ± 0.46 for the FC2 and FC3 compounds 
respectively. The conjugate inhibitor FC2 was therefore found to be more potent than 
Olaparib in the BRCA deficient cell lines. In fact, FC2 was found to be most effective in 
the BRCA1 deficient cell lines, indicating a mechanism of action that directly affects 
PARP function. FC2 is unlikely to break apart upon entry into the cell due to the strong 
amide bond linkage, and therefore must be exerting its inhibitory effect on PARP 
regardless of the 1-MLT inhibitor moiety.    
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Figure 4.2 Cytoxic efficacy of conjugate inhibitors on cell viability of HCC-1937 
 
 
Figure 4.3 Cytoxic efficacy of conjugate inhibitors on cell viability of A549 
 
A549 is a non-small cell lung carcinoma (NSCLC) cell line that does not have a germline 
BRCA mutation. Previous studies have shown that A549 is fairly resistant to Olaparib 
unless combined with concurrent radiation treatment. Our compounds were tested in this 
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cell line to determine efficacy in a lung cancer cell line since lung cancers are the most 
prevalent form of cancer. The previous trend continued with the conjugate inhibitors 
achieving much lower IC50 values than their parent inhibitor counterparts.   
 
 
Figure 4.4 Cytoxic efficacy of conjugate inhibitors on cell viability of OVCAR8 
 
We also tested our compounds in OVCAR8 cells, an ovarian cell line that is susceptible 
to multiple BRCA1 mutations. Our results showed FC2 and FC3 to be more toxic than 
monotreatment with the PARP inhibitor Olaparib or the IDO inhibitor 1-MLT. 
FC2 in particular proved to be particularly cytoxic, even without an easily degradable 
linker joining the conjugates. FC3’s ester linker could be responsible for the variance in 
potency between cell lines. The compound could be degrading upon entry into the cell 
and losing its effectiveness since it has been shown that Olaparib and 1-MLT both have 
much weaker IC50 values as monotherapies.   
 




O V C A R 8














O L A P A R IB
62 
 
Table 4.1 Cytoxic efficacy of conjugate inhibitors on cell viability of OVCAR8 
 
1-MLT was not found to be particularly active in any of the tested cell lines. This is 
primarily due to the fact that none of the current cell lines endogenously express IDO. 
The effectiveness of the conjugate inhibitors compared to single treatment with 1-MLT 
and IDO are summarized in table 4.1. The compound FC2 shows promising cytotoxicity 
in all cell lines and could be utilized as a probe in future analysis.  
4.3 Future Directions 
While the cell viability data proves our conjugate compounds are much more potent than 
the small molecule inhibitors they were derived from, there is more work needed to fully 
characterize the relationship between PARP and IDO. No cell lines that endogenously 
express IDO were tested, depriving us of information on whether our conjugate inhibitors 
were affecting IDO as well. Kynurenine detection experiments in cell lines that over 
express IDO would shine light on whether our compound directly effects IDO or is 
exacting its effect through an alternate pathway. Measuring the level of DNA damage and 
Cell Line IC50 
  FC2 FC3 OLAPARIB 1MLT 
A549 5.37 ±   0.23 18.20  ± 0.18 19.95 ± 1.66 22.91  ± 2.67 
HCC1937 3.63 ±    0.12 5.97± 0.46 14.79± 3.28 19.95± 1.07 
MDA-MB-231 6.17 ±    0.09 13.48±1.07 16.59-± 2.07 12.30± 1.88 
OVCAR8 5.62 ±    0.12 7.76 ±  0.16 18.20 ± 1.22 29.51 ± 3.27 
63 
 
PARP expression upon treatment with the conjugate drugs would help determine if our 
compounds were perturbing the DNA damage response.  
To fully understand the interplay between IDO and PARP, co-co culture experiments 
with activated macrophages and T-cells would need to be run. These multi-cell cultures 
would elucidate novel mechanisms of action and synergy between IDO and PARP since 
IDO production is often induced by signals from peripheral cells. The role of PARP in 
the recruitment, activation, and differentiation  of peripheral cells could then be studied 
upon inhibition with conjugate inhibitors. NAD/NADH levels would also need to be 
monitored in these systems to look at energy usage and mitochondrial activity in the 
tumor micro environment. These tests would provide an in depth exploration of any 
synergy or interplay between IDO and PARP and could provide hints at new targets for 
small molecule immunotherapeutics.      
4.4 Experimental Procedures  
Cell Culture198 
All human immortalized cell lines were obtained from the American Type Culture 
Collection (ATCC) and were cultured per ATCC propagation instructions; cells were 
routinely grown in a humidified incubator at 37 °C with 5% CO2. H460, HCC1937 
human cells were grown in RPMI containing 10% FBS, 1% Penicillin/ Streptomycin, 
4mM glutamine. MDA-MB-231, A549 cells were grown in DMEM containing 10% FBS, 
1% Penicillin/ Streptomycin, 4mM glutamine. All media and supplements were obtained 
from VWR, USA. 
 
MTT Assay198 
Cells were counted to make a solution of 20,000 cells/mL. 100 mL of the cell solution 
was transferred to the desired wells on a clear 96-well plate. Cells were incubated 
overnight at 37 oC to allow cells to adhere to the plate. After incubation solutions of the 
compounds to be tested were prepared in a minimal volume of DMSO. 1-MLT solutions 
were dissolved in 0.2 M NaOH in H20/DMSO to ensure complete dissolution. 
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Compound solutions were diluted to the appropriate volume with media, so that the 
highest concentration is 3x the desired maximum within the well plate 
50 mL of the desired concentration was added to the top 3 consecutive vertical wells. A 
second compound  was added to the bottom 3 consecutive vertical wells. The process was 
continued via serial dilution until all wells were filled. Cells were incubated for 72 h at 
37 oC. A 2 mg/mL solution of MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) dissolved in PBS  was added (50 mL per well) to each of 
the test wells in the dark. The plates were wrapped in foil and incubated 4 hours at 
37 oC.  The plates were then removed from the incubator and all media was removed 
from the well plates via suctioning with the multichannel pipette. 100 mL of DMSO was 
then added to each well.  A Magellan plate reader was used to read the plates using  the 
MTT assay protocol: 570nm, 3 flashes, 5 second orbital rotation. Data was plotted in 
GraphPad Prism 6. 
Crystal Violet Assay198 
Follow MTT protocol for treatment of cells. After the 72 h incubation period, remove 
media from the wells. Wells were gently rinsed with 100 mL of PBS. The PBS was 
removed and 100 µL of 1% glutaraldehyde solution was added to each well. Plates were 
incubated 10 minutes in the incubator.  The solution was removed and the plates were 
dipped in H2O and then allowed to dry. 50 µL of Crystal violet staining solution was then 
added to each well the plates were incubated at room temp while rocking  at 20 rpm for 
20 minutes.  Plates were inverted and gently tapped on a paper towel to eliminate excess 
water. Plates were then placed in a non-sterile incubator for 2 hours to accelerate drying. 
Upon completion of drying, 190 µL of methanol was added to each well. Plates were read 





















13-Nov-2020      10:50:43SYNAPT-G2#NotSet
m/z



































13-Nov-2020      10:50:43SYNAPT-G2#NotSet
m/z












































































13-Nov-2020      10:44:21SYNAPT-G2#NotSet
m/z





























13-Nov-2020      10:44:21SYNAPT-G2#NotSet
m/z












































































































































































1. Prendergast, G. C.;  Smith, C.;  Thomas, S.;  Mandik-Nayak, L.;  Laury-Kleintop, 
L.;  Metz, R.; Muller, A. J., Indoleamine 2,3-dioxygenase pathways of pathgenic 
inflammation and immune escape in cancer. Cancer immunology, immunotherapy : CII 
2014, 63 (7), 721-735. 
2. Prendergast, G. C., Immune escape as a fundamental trait of cancer: focus on IDO. 
Oncogene 2008, 27, 3889. 
3. Soliman, H.;  Mediavilla-Varela, M.; Antonia, S., Indoleamine 2,3-Dioxygenase: 
Is It an Immune Suppressor? Cancer journal (Sudbury, Mass.) 2010, 16 (4), 
10.1097/PPO.0b013e3181eb3343. 
4. Interest in IDO inhibitors remains high. C&EN Global Enterprise 2018, 96 (14), 
12-12. 
5. Incyte drug failure casts shadow on IDO class. C&EN Global Enterprise 2018, 96 
(16), 11-11. 
6. Companies Scaling Back IDO1 Inhibitor Trials. Cancer Discovery 2018. 
7. Bilir, C.; Sarisozen, C., Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a 
checkpoint controller? Journal of Oncological Sciences 2017, 3 (2), 52-56. 
8. Munn, D. H.;  Zhou, M.;  Attwood, J. T.;  Bondarev, I.;  Conway, S. J.;  Marshall, 
B.;  Brown, C.; Mellor, A. L., Prevention of Allogeneic Fetal Rejection by Tryptophan 
Catabolism. Science 1998, 281 (5380), 1191-1193. 
9. Grohmann, U.;  Fallarino, F.; Puccetti, P., Tolerance, DCs and tryptophan: much 
ado about IDO. Trends in Immunology 2003, 24 (5), 242-248. 
10. Uyttenhove, C.;  Pilotte, L.;  Théate, I.;  Stroobant, V.;  Colau, D.;  Parmentier, N.;  
Boon, T.; Van den Eynde, B. J., Evidence for a tumoral immune resistance mechanism 
based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine 2003, 
9, 1269. 
11. Nelson, B. H., The impact of T-cell immunity on ovarian cancer outcomes. 
Immunological Reviews 2008, 222 (1), 101-116. 
12. Zhang, L.;  Conejo-Garcia, J. R.;  Katsaros, D.;  Gimotty, P. A.;  Massobrio, M.;  
Regnani, G.;  Makrigiannakis, A.;  Gray, H.;  Schlienger, K.;  Liebman, M. N.;  Rubin, S. 
C.; Coukos, G., Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian 
Cancer. New England Journal of Medicine 2003, 348 (3), 203-213. 
13. Zhao, Q.;  Wang, P.-p.;  Huang, Z.-l.;  Peng, L.;  Lin, C.;  Gao, Z.; Su, S., Tumoral 
indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes 
collaboration in hepatocellular carcinoma. Oncotarget 2016, 7 (12), 14781-14790. 
14. Kazuhiko Ino, Y. T. A. K. S. T. Y. M.; Sawako, M., Role of the Immune Tolerance-
Inducing Molecule Indoleamine 2,3-Dioxygenase in Gynecologic Cancers. Journal of 
Cancer Science & Therapy 2013, 5 (8), -. 
15. Vigneron, N.;  van Baren, N.; Van den Eynde, B. J., Expression profile of the 
human IDO1 protein, a cancer drug target involved in tumoral immune resistance. 
Oncoimmunology 2015, 4 (5), e1003012. 
16. Yoshida, N.;  Ino, K.;  Ishida, Y.;  Kajiyama, H.;  Yamamoto, E.;  Shibata, K.;  
Terauchi, M.;  Nawa, A.;  Akimoto, H.;  Takikawa, O.;  Isobe, K.-i.; Kikkawa, F., 
Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells 
74 
 
Induces Rapid Tumor Growth in a Mouse Xenograft Model. Clinical Cancer Research 
2008, 14 (22), 7251-7259. 
17. Okamoto, A.;  Nikaido, T.;  Ochiai, K.;  Takakura, S.;  Saito, M.;  Aoki, Y.;  Ishii, 
N.;  Yanaihara, N.;  Yamada, K.;  Takikawa, O.;  Kawaguchi, R.;  Isonishi, S.;  Tanaka, T.; 
Urashima, M., Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in 
Gene Expression Profiles of Serous Ovarian Cancer Cells. Clinical Cancer Research 2005, 
11 (16), 6030-6039. 
18. Hornyák, L.;  Dobos, N.;  Koncz, G.;  Karányi, Z.;  Páll, D.;  Szabó, Z.;  Halmos, 
G.; Székvölgyi, L., The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, 
Diagnostics, and Therapy. Frontiers in Immunology 2018, 9 (151). 
19. Muller, A. J.;  DuHadaway, J. B.;  Donover, P. S.;  Sutanto-Ward, E.; Prendergast, 
G. C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the 
cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine 2005, 
11, 312. 
20. Frumento, G.;  Rotondo, R.;  Tonetti, M.;  Damonte, G.;  Benatti, U.; Ferrara, G. 
B., Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer 
Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase. The Journal of Experimental 
Medicine 2002, 196 (4), 459-468. 
21. Smith, C.;  Chang, M. Y.;  Parker, K. H.;  Beury, D. W.;  DuHadaway, J. B.;  Flick, 
H. E.;  Boulden, J.;  Sutanto-Ward, E.;  Soler, A. P.;  Laury-Kleintop, L. D.;  Mandik-
Nayak, L.;  Metz, R.;  Ostrand-Rosenberg, S.;  Prendergast, G. C.; Muller, A. J., IDO Is a 
Nodal Pathogenic Driver of Lung Cancer and Metastasis Development. Cancer Discovery 
2012, 2 (8), 722-735. 
22. Prendergast, G. C.; Jaffee, E. M., Cancer Immunotherapy: Immune Suppression 
and Tumor Growth. Elsevier Science: 2013. 
23. O'Sullivan, B. J.;  Pai, S.;  Street, S.;  An, X.;  MacDonald, K. P. A.;  Wong, M.;  
Strutton, G.;  Gerondakis, S.;  Steptoe, R. J.;  Fazekas de St. Groth, B.;  Hill, G. R.; Thomas, 
R., Immunotherapy with Costimulatory Dendritic Cells To Control Autoimmune 
Inflammation. J. Immunol. 2011, 187 (8), 4018-4030. 
24. Paveglio, S. A.;  Allard, J.;  Foster Hodgkins, S. R.;  Ather, J. L.;  Bevelander, M.;  
Campbell, J. M.;  Whittaker LeClair, L. A.;  McCarthy, S. M.;  van der Vliet, A.;  Suratt, 
B. T.;  Boyson, J. E.;  Uematsu, S.;  Akira, S.; Poynter, M. E., Airway epithelial 
indoleamine 2,3-dioxygenase inhibits CD4+ T cells during Aspergillus fumigatus antigen 
exposure. Am. J. Respir. Cell Mol. Biol. 2011, 44 (1), 11-23. 
25. Koch, L. K.;  Bucher, C.;  Panoskaltsis-Mortari, A.;  Mellor, A. L.;  Munn, D. H.; 
Blazar, B. R., Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase 
(IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009, 114 
(24), 5062-5070. 
26. Lin, Y. C.;  Goto, S.;  Tateno, C.;  Nakano, T.;  Cheng, Y. F.;  Jawan, B.;  Kao, Y. 
H.;  Hsu, L. W.;  Lai, C. Y.;  Yoshizato, K.; Chen, C. L., Induction of Indoleamine 2,3-
Dioxygenase in Livers Following Hepatectomy Prolongs Survival of Allogeneic 
Hepatocytes After Transplantation. Transplant. Proc. 2008, 40 (8), 2706-2708. 
27. Lin, Y.-C.;  Chen, C.-L.;  Nakano, T.;  Goto, S.;  Kao, Y.-H.;  Hsu, L.-W.;  Lai, C.-
Y.;  Jawan, B.;  Cheng, Y.-F.;  Tateno, C.; Yoshizato, K., Immunological role of 
indoleamine 2,3-dioxygenase in rat liver allograft rejection and tolerance. J. Gastroenterol. 
Hepatol. 2008, 23 (7, Pt. 2), e243-e250. 
75 
 
28. Lu, A.;  Zhang, J.;  Wang, L.;  Zhang, X.; Zhang, M., Role of indoleamine 2,3-
dioxygenase in an animal asthma model. Linchuang Erke Zazhi 2011, 29 (4), 301-306. 
29. Jia, S.;  Guo, P.;  Ge, X.;  Wu, H.;  Lu, J.; Fan, X., Overexpression of indoleamine 
2,3-dioxygenase contributes to the repair of human airway epithelial cells inhibited by 
dexamethasone via affecting the MAPK/ERK signaling pathway. Exp. Ther. Med. 2018, 
16 (1), 1-9. 
30. Liu, H.-y.;  Wang, F.-f.;  Miao, W.-w.;  Yin, K.-s.; Zhou, L.-f., Application of 
indoleamine 2,3-dioxygenase as new target for immunotherapy of bronchial asthma. 
Zhonghua Weishengwuxue He Mianyixue Zazhi 2012, 32 (9), 831-834. 
31. Ericsson, P.;  Hedbys, L.;  Salford, L.; Sjoegren, H.-O. Novel treatment method to 
induce immune tolerance to drugs. WO2016146842A1, 2016. 
32. Ericsson, P.;  Hedbys, L.;  Salford, L.; Sjogren, H.-O. Novel treatment method to 
induce immune tolerance to drugs comprising ex-vivo treating antigen-presenting cells 
with an inducer of IDO (indolamine dioxygenase) and transferring those cells back to the 
mammal. US20170014499A1, 2017. 
33. Asghar, K.;  Ashiq, M. T.;  Zulfiqar, B.;  Mahroo, A.;  Nasir, K.; Murad, S., 
Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-
induced liver cirrhosis. Exp Ther Med 2015, 9 (3), 901-904. 
34. Asghar, K.;  Farooq, A.;  Zulfiqar, B.; Rashid, M. U., Indoleamine 2,3-dioxygenase: 
As a potential prognostic marker and immunotherapeutic target for hepatocellular 
carcinoma. World Journal of Gastroenterology 2017, 23 (13), 2286-2293. 
35. Nagano, J.;  Shimizu, M.;  Hara, T.;  Shirakami, Y.;  Kochi, T.;  Nakamura, N.;  
Ohtaki, H.;  Ito, H.;  Tanaka, T.;  Tsurumi, H.;  Saito, K.;  Seishima, M.; Moriwaki, H., 
Effects of Indoleamine 2,3-Dioxygenase Deficiency on High-Fat Diet-Induced Hepatic 
Inflammation. PLoS ONE 2013, 8 (9), e73404. 
36. Niinisalo, P.;  Oksala, N.;  Levula, M.;  Pelto-Huikko, M.;  Jaervinen, O.;  Salenius, 
J.-P.;  Kytoemaeki, L.;  Soini, J. T.;  Kaehoenen, M.;  Laaksonen, R.;  Hurme, M.; 
Lehtimaeki, T., Activation of indoleamine 2,3-dioxygenase-induced tryptophan 
degradation in advanced atherosclerotic plaques: Tampere Vascular Study. Ann. Med. 
(London, U. K.) 2010, 42 (1), 55-63. 
37. Vareki, S. M.;  Rytelewski, M.;  Figueredo, R.;  Chen, D.;  Ferguson, P. J.;  Vincent, 
M.;  Min, W.;  Zheng, X.; Koropatnick, J., Indoleamine 2,3-dioxygenase mediates immune-
independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. 
Oncotarget 2014, 5 (9), 2778-2791. 
38. Maleki Vareki, S.;  Chen, D.;  Di Cresce, C.;  Ferguson, P. J.;  Figueredo, R.;  
Pampillo, M.;  Rytelewski, M.;  Vincent, M.;  Min, W.;  Zheng, X.; Koropatnick, J., IDO 
Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and 
Methoxyamine in Human Cancer Cells. PLOS ONE 2015, 10 (11), e0143435. 
39. Ino, K.;  Yoshida, N.;  Kajiyama, H.;  Shibata, K.;  Yamamoto, E.;  Kidokoro, K.;  
Takahashi, N.;  Terauchi, M.;  Nawa, A.;  Nomura, S.;  Nagasaka, T.;  Takikawa, O.; 
Kikkawa, F., Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial 
cancer. British journal of cancer 2006, 95 (11), 1555-1561. 
40. Brandacher, G.;  Perathoner, A.;  Ladurner, R.;  Schneeberger, S.;  Obrist, P.;  
Winkler, C.;  Werner, E. R.;  Werner-Felmayer, G.;  Weiss, H. G.;  G√∂bel, G.;  Margreiter, 
R.;  K√∂nigsrainer, A.;  Fuchs, D.; Amberger, A., Prognostic value of indoleamine 2,3-
76 
 
dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clinical 
Cancer Research 2006, 12 (4), 1144-1151. 
41. Munn, D. H.; Mellor, A. L., IDO in the Tumor Microenvironment: Inflammation, 
Counter-Regulation, and Tolerance. Trends in Immunology 2016, 37 (3), 193-207. 
42. Munn, D. H.; Mellor, A. L., Indoleamine 2,3 dioxygenase and metabolic control of 
immune responses. Trends in Immunology 2013, 34 (3), 137-143. 
43. Munn, D. H.;  Sharma, M. D.;  Baban, B.;  Harding, H. P.;  Zhang, Y.;  Ron, D.; 
Mellor, A. L., GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction 
in Response to Indoleamine 2,3-Dioxygenase. Immunity 2005, 22 (5), 633-642. 
44. Peter, C.;  Waldmann, H.; Cobbold, S. P., mTOR signalling and metabolic 
regulation of T cell differentiation. Current Opinion in Immunology 2010, 22 (5), 655-661. 
45. Ninomiya, S.;  Nakamura, N.;  Kitagawa, J.;  Hara, T.;  Shimizu, M.; Tsurumi, H., 
The Roles of Aryl Hydrocarbon Receptor in T Cells at IDO-Positive Tumor 
Microenvironment. Blood 2016, 128 (22), 3693-3693. 
46. Cheong, J. E.; Sun, L., Targeting the IDO1/TDO2&#x2013;KYN&#x2013;AhR 
Pathway for Cancer Immunotherapy &#x2013; Challenges and Opportunities. Trends in 
Pharmacological Sciences 2018, 39 (3), 307-325. 
47. Van de Velde, L.-A.;  Guo, X.-Z. J.;  Barbaric, L.;  Smith, A. M.;  Oguin, T. H., 
3rd;  Thomas, P. G.; Murray, P. J., Stress Kinase GCN2 Controls the Proliferative Fitness 
and Trafficking of Cytotoxic T Cells Independent of Environmental Amino Acid Sensing. 
Cell reports 2016, 17 (9), 2247-2258. 
48. Dong, J.;  Qiu, H.;  Garcia-Barrio, M.;  Anderson, J.; Hinnebusch, A. G., Uncharged 
tRNA Activates GCN2 by Displacing the Protein Kinase Moiety from a Bipartite tRNA-
Binding Domain. Molecular Cell 2000, 6 (2), 269-279. 
49. Rao, R. V.;  Ellerby, H. M.; Bredesen, D. E., Coupling endoplasmic reticulum stress 
to the cell death program. Cell Death And Differentiation 2004, 11, 372. 
50. Fallarino, F.;  Grohmann, U.;  You, S.;  McGrath, B. C.;  Cavener, D. R.;  Vacca, 
C.;  Orabona, C.;  Bianchi, R.;  Belladonna, M. L.;  Volpi, C.;  Santamaria, P.;  Fioretti, M. 
C.; Puccetti, P., The Combined Effects of Tryptophan Starvation and Tryptophan 
Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype 
in Naive T Cells. The Journal of Immunology 2006, 176 (11), 6752-6761. 
51. Sharma, M. D.;  Baban, B.;  Chandler, P.;  Hou, D.-Y.;  Singh, N.;  Yagita, H.;  
Azuma, M.;  Blazar, B. R.;  Mellor, A. L.; Munn, D. H., Plasmacytoid dendritic cells from 
mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-
dioxygenase. The Journal of clinical investigation 2007, 117 (9), 2570-2582. 
52. Sonner, J. K.;  Deumelandt, K.;  Ott, M.;  Thomé, C. M.;  Rauschenbach, K. J.;  
Schulz, S.;  Munteanu, B.;  Mohapatra, S.;  Adam, I.;  Hofer, A.-C.;  Feuerer, M.;  Opitz, 
C. A.;  Hopf, C.;  Wick, W.; Platten, M., The stress kinase GCN2 does not mediate 
suppression of antitumor T cell responses by tryptophan catabolism in experimental 
melanomas. Oncoimmunology 2016, 5 (12), e1240858. 
53. Costa-Mattioli, M.;  Gobert, D.;  Harding, H.;  Herdy, B.;  Azzi, M.;  Bruno, M.;  
Bidinosti, M.;  Ben Mamou, C.;  Marcinkiewicz, E.;  Yoshida, M.;  Imataka, H.;  Cuello, 
A. C.;  Seidah, N.;  Sossin, W.;  Lacaille, J.-C.;  Ron, D.;  Nader, K.; Sonenberg, N., 
Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha 
kinase GCN2. Nature 2005, 436 (7054), 1166-1173. 
77 
 
54. Metz, R.;  Rust, S.;  Duhadaway, J. B.;  Mautino, M. R.;  Munn, D. H.;  Vahanian, 
N. N.;  Link, C. J.; Prendergast, G. C., IDO inhibits a tryptophan sufficiency signal that 
stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. 
Oncoimmunology 2012, 1 (9), 1460-1468. 
55. Johnson, T. S.; Munn, D. H., Host Indoleamine 2,3-Dioxygenase: Contribution to 
Systemic Acquired Tumor Tolerance. Immunological Investigations 2012, 41 (6-7), 765-
797. 
56. Chuang, H.-C.;  Lan, J.-L.;  Chen, D.-Y.;  Yang, C.-Y.;  Chen, Y.-M.;  Li, J.-P.;  
Huang, C.-Y.;  Liu, P.-E.;  Wang, X.; Tan, T.-H., The kinase GLK controls autoimmunity 
and NF-κB signaling by activating the kinase PKC-θ in T cells. Nature Immunology 2011, 
12, 1113. 
57. Kim, L. C.;  Cook, R. S.; Chen, J., mTORC1 and mTORC2 in cancer and the tumor 
microenvironment. Oncogene 2017, 36 (16), 2191-2201. 
58. Paquette, M.;  El-Houjeiri, L.; Pause, A., mTOR Pathways in Cancer and 
Autophagy. Cancers 2018, 10 (1), 18. 
59. Ilagan, E.; Manning, B. D., Emerging role of mTOR in the response to cancer 
therapeutics. Trends in cancer 2016, 2 (5), 241-251. 
60. Moon, Y. W.;  Hajjar, J.;  Hwu, P.; Naing, A., Targeting the indoleamine 2,3-
dioxygenase pathway in cancer. Journal for Immunotherapy of Cancer 2015, 3, 51. 
61. Nguyen, N. T.;  Kimura, A.;  Nakahama, T.;  Chinen, I.;  Masuda, K.;  Nohara, K.;  
Fujii-Kuriyama, Y.; Kishimoto, T., Aryl hydrocarbon receptor negatively regulates 
dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proceedings of the 
National Academy of Sciences of the United States of America 2010, 107 (46), 19961-
19966. 
62. Munn, D. H.; Mellor, A. L., Chapter 33 - IDO Pathway: Effect on Foxp3+ Tregs 
and Cancer. In Cancer Immunotherapy (Second Edition), Prendergast, G. C.; Jaffee, E. M., 
Eds. Academic Press: San Diego, 2013; pp 583-596. 
63. Opitz, C. A.;  Litzenburger, U. M.;  Sahm, F.;  Ott, M.;  Tritschler, I.;  Trump, S.;  
Schumacher, T.;  Jestaedt, L.;  Schrenk, D.;  Weller, M.;  Jugold, M.;  Guillemin, G. J.;  
Miller, C. L.;  Lutz, C.;  Radlwimmer, B.;  Lehmann, I.;  von Deimling, A.;  Wick, W.; 
Platten, M., An endogenous tumour-promoting ligand of the human aryl hydrocarbon 
receptor. Nature 2011, 478, 197. 
64. Gramatzki, D.;  Pantazis, G.;  Schittenhelm, J.;  Tabatabai, G.;  Köhle, C.;  Wick, 
W.;  Schwarz, M.;  Weller, M.; Tritschler, I., Aryl hydrocarbon receptor inhibition 
downregulates the TGF-β/Smad pathway in human glioblastoma cells. Oncogene 2009, 28, 
2593. 
65. Vacher, S.;  Castagnet, P.;  Chemlali, W.;  Lallemand, F.;  Meseure, D.;  Pocard, 
M.;  Bieche, I.; Perrot-Applanat, M., High AHR expression in breast tumors correlates with 
expression of genes from several signaling pathways namely inflammation and 
endogenous tryptophan metabolism. PLOS ONE 2018, 13 (1), e0190619. 
66. Xue, P.;  Fu, J.; Zhou, Y., The Aryl Hydrocarbon Receptor and Tumor Immunity. 
Frontiers in immunology 2018, 9, 286-286. 
67. Murray, I. A.;  Patterson, A. D.; Perdew, G. H., Aryl hydrocarbon receptor ligands 
in cancer: friend and foe. Nature reviews. Cancer 2014, 14 (12), 801-814. 
78 
 
68. Maltepe, E.;  Schmidt, J. V.;  Baunoch, D.;  Bradfield, C. A.; Simon, M. C., 
Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking 
the protein ARNT. Nature 1997, 386, 403. 
69. Litzenburger, U. M.;  Opitz, C. A.;  Sahm, F.;  Rauschenbach, K. J.;  Trump, S.;  
Winter, M.;  Ott, M.;  Ochs, K.;  Lutz, C.;  Liu, X.;  Anastasov, N.;  Lehmann, I.;  Höfer, 
T.;  von Deimling, A.;  Wick, W.; Platten, M., Constitutive IDO expression in human 
cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. 
Oncotarget 2014, 5 (4), 1038-1051. 
70. Schlezinger Jennifer, J.;  Liu, D.;  Farago, M.;  Seldin David, C.;  Belguise, K.;  
Sonenshein Gail, E.; Sherr David, H., A role for the aryl hydrocarbon receptor in mammary 
gland tumorigenesis. In Biological Chemistry, 2006; Vol. 387, p 1175. 
71. Sarkar, S. A.;  Wong, R.;  Hackl, S. I.;  Moua, O.;  Gill, R. G.;  Wiseman, A.;  
Davidson, H. W.; Hutton, J. C., Induction of Indoleamine 2,3-Dioxygenase by Interferon-
γ in Human Islets. Diabetes 2007, 56 (1), 72-79. 
72. Grohmann, U.;  Bianchi, R.;  Belladonna, M. L.;  Silla, S.;  Fallarino, F.;  Fioretti, 
M. C.; Puccetti, P., IFN-γ Inhibits Presentation of a Tumor/Self Peptide by 
CD8α<sup>−</sup> Dendritic Cells Via Potentiation of the CD8α<sup>+</sup> Subset. 
The Journal of Immunology 2000, 165 (3), 1357-1363. 
73. Mellor, A. L.;  Lemos, H.; Huang, L., Indoleamine 2,3-Dioxygenase and Tolerance: 
Where Are We Now? Frontiers in Immunology 2017, 8 (1360). 
74. Muller, A. J.;  Sharma, M. D.;  Chandler, P. R.;  DuHadaway, J. B.;  Everhart, M. 
E.;  Johnson, B. A.;  Kahler, D. J.;  Pihkala, J.;  Soler, A. P.;  Munn, D. H.;  Prendergast, 
G. C.; Mellor, A. L., Chronic inflammation that facilitates tumor progression creates local 
immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the 
National Academy of Sciences 2008, 105 (44), 17073-17078. 
75. Braun, D.;  Longman, R. S.; Albert, M. L., A two-step induction of indoleamine 
2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106 (7), 
2375-2381. 
76. Samelson-Jones, B. J.; Yeh, S.-R., Interactions between Nitric Oxide and 
Indoleamine 2,3-Dioxygenase. Biochemistry 2006, 45 (28), 8527-8538. 
77. Orabona, C.;  Pallotta, M. T.;  Volpi, C.;  Fallarino, F.;  Vacca, C.;  Bianchi, R.;  
Belladonna, M. L.;  Fioretti, M. C.;  Grohmann, U.; Puccetti, P., SOCS3 drives proteasomal 
degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent 
tolerogenesis. Proceedings of the National Academy of Sciences of the United States of 
America 2008, 105 (52), 20828-20833. 
78. Spranger, S.;  Spaapen, R. M.;  Zha, Y.;  Williams, J.;  Meng, Y.;  Ha, T. T.; 
Gajewski, T. F., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor 
microenvironment is driven by CD8(+) T cells. Science translational medicine 2013, 5 
(200), 200ra116-200ra116. 
79. Sugimoto, H.;  Oda, S.-i.;  Otsuki, T.;  Hino, T.;  Yoshida, T.; Shiro, Y., Crystal 
structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O<sub>2</sub> 
incorporation by a heme-containing dioxygenase. Proceedings of the National Academy of 
Sciences of the United States of America 2006, 103 (8), 2611-2616. 
80. Dounay, A. B.;  Tuttle, J. B.; Verhoest, P. R., Challenges and Opportunities in the 
Discovery of New Therapeutics Targeting the Kynurenine Pathway. Journal of Medicinal 
Chemistry 2015, 58 (22), 8762-8782. 
79 
 
81. Basran, J.;  Booth, E. S.;  Lee, M.;  Handa, S.; Raven, E. L., Analysis of Reaction 
Intermediates in Tryptophan 2,3-Dioxygenase: A Comparison with Indoleamine 2,3-
Dioxygenase. Biochemistry 2016, 55 (49), 6743-6750. 
82. Srivastava, S., Emerging therapeutic roles for NAD(+) metabolism in 
mitochondrial and age-related disorders. Clinical and Translational Medicine 2016, 5, 25. 
83. Efimov, I.;  Basran, J.;  Sun, X.;  Chauhan, N.;  Chapman, S. K.;  Mowat, C. G.; 
Raven, E. L., The Mechanism of Substrate Inhibition in Human Indoleamine 2,3-
Dioxygenase. Journal of the American Chemical Society 2012, 134 (6), 3034-3041. 
84. Fang, K.;  Dong, G.;  Li, Y.;  He, S.;  Wu, Y.;  Wu, S.;  Wang, W.; Sheng, C., 
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 
(HDAC) Dual Inhibitors. ACS Medicinal Chemistry Letters 2018, 9 (4), 312-317. 
85. Yang, S.;  Li, X.;  Hu, F.;  Li, Y.;  Yang, Y.;  Yan, J.;  Kuang, C.; Yang, Q., 
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-
Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing 
Mice. Journal of Medicinal Chemistry 2013, 56 (21), 8321-8331. 
86. Cady, S. G.; Sono, M., 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-
alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the 
sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. 
Arch Biochem Biophys 1991, 291 (2), 326-333. 
87. Lewis, H. C.;  Chinnadurai, R.;  Bosinger, S. E.; Galipeau, J., The IDO inhibitor 1-
methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal 
stromal cells. Oncotarget 2017, 8 (54), 91914-91927. 
88. Opitz, C. A.;  Litzenburger, U. M.;  Opitz, U.;  Sahm, F.;  Ochs, K.;  Lutz, C.;  Wick, 
W.; Platten, M., The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan 
upregulates IDO1 in human cancer cells. PloS one 2011, 6 (5), e19823-e19823. 
89. Degterev, A.;  Huang, Z.;  Boyce, M.;  Li, Y.;  Jagtap, P.;  Mizushima, N.;  Cuny, 
G. D.;  Mitchison, T. J.;  Moskowitz, M. A.; Yuan, J., Chemical inhibitor of nonapoptotic 
cell death with therapeutic potential for ischemic brain injury. Nature Chemical Biology 
2005, 1, 112. 
90. Dolušić, E.;  Larrieu, P.;  Blanc, S.;  Sapunaric, F.;  Norberg, B.;  Moineaux, L.;  
Colette, D.;  Stroobant, V.;  Pilotte, L.;  Colau, D.;  Ferain, T.;  Fraser, G.;  Galleni, M.;  
Frère, J.-M.;  Masereel, B.;  Van den Eynde, B.;  Wouters, J.; Frédérick, R., Indol-2-yl 
ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. Bioorg Med Chem 
2011, 19 (4), 1550-1561. 
91. Ino, K., Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. 
Current Opinion in Obstetrics and Gynecology 2011, 23 (1), 13-18. 
92. Crosignani, S.;  Bingham, P.;  Bottemanne, P.;  Cannelle, H.;  Cauwenberghs, S.;  
Cordonnier, M.;  Dalvie, D.;  Deroose, F.;  Feng, J. L.;  Gomes, B.;  Greasley, S.;  Kaiser, 
S. E.;  Kraus, M.;  Négrerie, M.;  Maegley, K.;  Miller, N.;  Murray, B. W.;  Schneider, M.;  
Soloweij, J.;  Stewart, A. E.;  Tumang, J.;  Torti, V. R.;  Van Den Eynde, B.; Wythes, M., 
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-
Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its 
Characterization as a Potential Clinical Candidate. Journal of Medicinal Chemistry 2017, 
60 (23), 9617-9629. 
93. Coluccia, A.;  Passacantilli, S.;  Famiglini, V.;  Sabatino, M.;  Patsilinakos, A.;  
Ragno, R.;  Mazzoccoli, C.;  Sisinni, L.;  Okuno, A.;  Takikawa, O.;  Silvestri, R.; La 
80 
 
Regina, G., New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling 
Studies, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry 2016, 59 
(21), 9760-9773. 
94. Prendergast, G. C.;  Malachowski, W. P.;  DuHadaway, J. B.; Muller, A. J., 
Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Research 2017, 77 (24), 
6795-6811. 
95. Röhrig, U. F.;  Awad, L.;  Grosdidier, A.;  Larrieu, P.;  Stroobant, V.;  Colau, D.;  
Cerundolo, V.;  Simpson, A. J. G.;  Vogel, P.;  Van den Eynde, B. J.;  Zoete, V.; Michielin, 
O., Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors. Journal of Medicinal 
Chemistry 2010, 53 (3), 1172-1189. 
96. Röhrig, U. F.;  Majjigapu, S. R.;  Grosdidier, A.;  Bron, S.;  Stroobant, V.;  Pilotte, 
L.;  Colau, D.;  Vogel, P.;  Van den Eynde, B. J.;  Zoete, V.; Michielin, O., Rational Design 
of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition. Journal of 
Medicinal Chemistry 2012, 55 (11), 5270-5290. 
97. Röhrig, U. F.;  Majjigapu, S. R.;  Chambon, M.;  Bron, S.;  Pilotte, L.;  Colau, D.;  
Van den Eynde, B. J.;  Turcatti, G.;  Vogel, P.;  Zoete, V.; Michielin, O., Detailed analysis 
and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 
(IDO1) inhibitors. European Journal of Medicinal Chemistry 2014, 84, 284-301. 
98. Röhrig, U. F.;  Majjigapu, S. R.;  Vogel, P.;  Zoete, V.; Michielin, O., Challenges 
in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Journal of 
Medicinal Chemistry 2015, 58 (24), 9421-9437. 
99. Röhrig, U. F.;  Zoete, V.; Michielin, O., The Binding Mode of N-Hydroxyamidines 
to Indoleamine 2,3-Dioxygenase 1 (IDO1). Biochemistry 2017, 56 (33), 4323-4325. 
100. Kumar, S.;  Malachowski, W. P.;  DuHadaway, J. B.;  LaLonde, J. M.;  Carroll, P. 
J.;  Jaller, D.;  Metz, R.;  Prendergast, G. C.; Muller, A. J., Indoleamine 2,3-Dioxygenase 
Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. 
Journal of Medicinal Chemistry 2008, 51 (6), 1706-1718. 
101. Centko, R. M.;  Steinø, A.;  Rosell, F. I.;  Patrick, B. O.;  de Voogd, N.;  Mauk, A. 
G.; Andersen, R. J., Indoleamine 2,3-Dioxygenase Inhibitors Isolated from the Sponge 
Xestospongia vansoesti: Structure Elucidation, Analogue Synthesis, and Biological 
Activity. Organic Letters 2014, 16 (24), 6480-6483. 
102. Pasceri, R.;  Siegel, D.;  Ross, D.; Moody, C. J., Aminophenoxazinones as 
Inhibitors of Indoleamine 2,3-Dioxygenase (IDO). Synthesis of Exfoliazone and 
Chandrananimycin A. Journal of Medicinal Chemistry 2013, 56 (8), 3310-3317. 
103. Sono, M.; Cady, S. G., Enzyme kinetic and spectroscopic studies of inhibitor and 
effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-
phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry 1989, 
28 (13), 5392-5399. 
104. Kumar, S.;  Jaller, D.;  Patel, B.;  LaLonde, J. M.;  DuHadaway, J. B.;  
Malachowski, W. P.;  Prendergast, G. C.; Muller, A. J., Structure Based Development of 
Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase. Journal of 
Medicinal Chemistry 2008, 51 (16), 4968-4977. 
105. Carr, G.;  Chung, M. K. W.;  Mauk, A. G.; Andersen, R. J., Synthesis of 
Indoleamine 2,3-Dioxygenase Inhibitory Analogues of the Sponge Alkaloid Exiguamine 
A. Journal of Medicinal Chemistry 2008, 51 (9), 2634-2637. 
81 
 
106. Pereira, A.;  Vottero, E.;  Roberge, M.;  Mauk, A. G.; Andersen, R. J., Indoleamine 
2,3-Dioxygenase Inhibitors from the Northeastern Pacific Marine Hydroid Garveia 
annulata. Journal of Natural Products 2006, 69 (10), 1496-1499. 
107. Flick, H. E.;  Lalonde, J. M.;  Malachowski, W. P.; Muller, A. J., The Tumor-
Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1. International 
journal of tryptophan research : IJTR 2013, 6, 35-45. 
108. Bridewell, D. J. A.;  Sperry, J.;  Smith, J. R.;  Kosim-Satyaputra, P.;  Ching, L.-M.;  
Jamie, J. F.; Brimble, M. A., Natural Product-Inspired Pyranonaphthoquinone Inhibitors 
of Indoleamine 2,3-Dioxygenase-1 (IDO-1)<a class="reftools" href="#FN1">*</a>. 
Australian Journal of Chemistry 2013, 66 (1), 40-49. 
109. Carr, G.;  Tay, W.;  Bottriell, H.;  Andersen, S. K.;  Mauk, A. G.; Andersen, R. J., 
Plectosphaeroic Acids A, B, and C, Indoleamine 2,3-Dioxygenase Inhibitors Produced in 
Culture by a Marine Isolate of the Fungus Plectosphaerella cucumerina. Organic Letters 
2009, 11 (14), 2996-2999. 
110. Austin, C. J. D.;  Kahlert, J.;  Issa, F.;  Reed, J. H.;  Smith, J. R.;  Ioppolo, J. A.;  
Ong, J. A.;  Jamie, J. F.;  Hibbs, D.; Rendina, L. M., The first indoleamine-2,3-
dioxygenase-1 (IDO1) inhibitors containing carborane. Dalton Transactions 2014, 43 (28), 
10719-10724. 
111. Carvalho, C.;  Siegel, D.;  Inman, M.;  Xiong, R.;  Ross, D.; Moody, C. J., 
Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and 
biological evaluation. Organic & Biomolecular Chemistry 2014, 12 (17), 2663-2674. 
112. Tourino, M. C.;  de Oliveira, E. M.;  Bellé, L. P.;  Knebel, F. H.;  Albuquerque, R. 
C.;  Dörr, F. A.;  Okada, S. S.;  Migliorini, S.;  Soares, I. S.; Campa, A., Tryptamine and 
dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive 
effect of peripheral blood mononuclear cells. Cell Biochemistry and Function 2013, 31 (5), 
361-364. 
113. Cheng, M.-F.;  Hung, M.-S.;  Song, J.-S.;  Lin, S.-Y.;  Liao, F.-Y.;  Wu, M.-H.;  
Hsiao, W.;  Hsieh, C.-L.;  Wu, J.-S.;  Chao, Y.-S.;  Shih, C.;  Wu, S.-Y.; Ueng, S.-H., 
Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as 
novel indoleamine 2,3-dioxygenase inhibitors. Bioorg Med Chem Lett 2014, 24 (15), 3403-
3406. 
114. Lin, S.-Y.;  Yeh, T.-K.;  Song, J.-S.;  Hung, M.-S.;  Cheng, M.-F.;  Liao, F.-Y.;  Li, 
A.-S.;  Cheng, S.-Y.;  Lin, L.-M.;  Chiu, C.-H.;  Wu, M.-H.;  Lin, Y.-J.;  Hsiao, W.;  Sun, 
M.;  Wang, Y.-H.;  Huang, C.-H.;  Tang, Y.-C.;  Chang, H.-H.;  Huang, Z.-T.;  Chao, Y.-
S.;  Shih, C.;  Pan, S.-L.;  Wu, S.-Y.;  Kuo, C.-C.; Ueng, S.-H., 4-Bromophenylhydrazinyl 
benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target 
inhibition and anti-tumor efficacy. Bioorganic Chemistry 2018, 77, 600-607. 
115. Matsuno, K.;  Yamazaki, H.;  Isaka, Y.;  Takai, K.;  Unno, Y.;  Ogo, N.;  Ishikawa, 
Y.;  Fujii, S.;  Takikawa, O.; Asai, A., Novel candesartan derivatives as indoleamine 2,3-
dioxygenase inhibitors. MedChemComm 2012, 3 (4), 475-479. 
116. Wu, Y.;  Xu, T.;  Liu, J.;  Ding, K.; Xu, J., Structural insights into the binding 
mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943. Biochemical and 
Biophysical Research Communications 2017, 487 (2), 339-343. 
117. Koblish, H. K.;  Hansbury, M. J.;  Bowman, K. J.;  Yang, G.;  Neilan, C. L.;  Haley, 
P. J.;  Burn, T. C.;  Waeltz, P.;  Sparks, R. B.;  Yue, E. W.;  Combs, A. P.;  Scherle, P. A.;  
Vaddi, K.; Fridman, J. S., Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase 
82 
 
Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing 
Tumors. Molecular Cancer Therapeutics 2010, 9 (2), 489-498. 
118. Yue, E. W.;  Douty, B.;  Wayland, B.;  Bower, M.;  Liu, X.;  Leffet, L.;  Wang, Q.;  
Bowman, K. J.;  Hansbury, M. J.;  Liu, C.;  Wei, M.;  Li, Y.;  Wynn, R.;  Burn, T. C.;  
Koblish, H. K.;  Fridman, J. S.;  Metcalf, B.;  Scherle, P. A.; Combs, A. P., Discovery of 
Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo 
Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model. Journal of 
Medicinal Chemistry 2009, 52 (23), 7364-7367. 
119. Jochems, C.;  Fantini, M.;  Fernando, R. I.;  Kwilas, A. R.;  Donahue, R. N.;  
Lepone, L. M.;  Grenga, I.;  Kim, Y.-S.;  Brechbiel, M. W.;  Gulley, J. L.;  Madan, R. A.;  
Heery, C. R.;  Hodge, J. W.;  Newton, R.;  Schlom, J.; Tsang, K. Y., The IDO1 selective 
inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor 
antigen-specific T cells. Oncotarget 2016, 7 (25), 37762-37772. 
120. Awuah, S. G.;  Zheng, Y.-R.;  Bruno, P. M.;  Hemann, M. T.; Lippard, S. J., A 
Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced 
Ovarian Cancer Immuno-Chemotherapy. Journal of the American Chemical Society 2015, 
137 (47), 14854-14857. 
121. Hua, S.;  Chen, F.;  Xu, G.; Gou, S., Multifunctional platinum(IV) complexes as 
immunostimulatory agents to promote cancer immunochemotherapy by inhibiting 
tryptophan-2,3-dioxygenase. European Journal of Medicinal Chemistry 2019, 169, 29-41. 
122. Nakashima, H.;  Uto, Y.;  Nakata, E.;  Nagasawa, H.;  Ikkyu, K.;  Hiraoka, N.;  
Nakashima, K.;  Sasaki, Y.;  Sugimoto, H.;  Shiro, Y.;  Hashimoto, T.;  Okamoto, Y.;  
Asakawa, Y.; Hori, H., Synthesis and biological activity of 1-methyl-tryptophan-
tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors. Bioorg 
Med Chem 2008, 16 (18), 8661-8669. 
123. Godin-Ethier, J.;  Hanafi, L.-A.;  Piccirillo, C. A.; Lapointe, R., Indoleamine 2,3-
Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives. 
Clinical Cancer Research 2011, 17 (22), 6985-6991. 
124. Qian, S.;  Zhang, M.;  Chen, Q.;  He, Y.;  Wang, W.; Wang, Z., IDO as a drug target 
for cancer immunotherapy: recent developments in IDO inhibitors discovery. RSC 
Advances 2016, 6 (9), 7575-7581. 
125. Yue, E. W.;  Sparks, R.;  Polam, P.;  Modi, D.;  Douty, B.;  Wayland, B.;  Glass, 
B.;  Takvorian, A.;  Glenn, J.;  Zhu, W.;  Bower, M.;  Liu, X.;  Leffet, L.;  Wang, Q.;  
Bowman, K. J.;  Hansbury, M. J.;  Wei, M.;  Li, Y.;  Wynn, R.;  Burn, T. C.;  Koblish, H. 
K.;  Fridman, J. S.;  Emm, T.;  Scherle, P. A.;  Metcalf, B.; Combs, A. P., INCB24360 
(Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) 
Inhibitor for Immuno-oncology. ACS Medicinal Chemistry Letters 2017, 8 (5), 486-491. 
126. Liu, X.;  Shin, N.;  Koblish, H. K.;  Yang, G.;  Wang, Q.;  Wang, K.;  Leffet, L.;  
Hansbury, M. J.;  Thomas, B.;  Rupar, M.;  Waeltz, P.;  Bowman, K. J.;  Polam, P.;  Sparks, 
R. B.;  Yue, E. W.;  Li, Y.;  Wynn, R.;  Fridman, J. S.;  Burn, T. C.;  Combs, A. P.;  Newton, 
R. C.; Scherle, P. A., Selective inhibition of IDO1 effectively regulates mediators of 
antitumor immunity. Blood 2010, 115 (17), 3520-3530. 
127. Li, M.;  Bolduc, A. R.;  Hoda, M. N.;  Gamble, D. N.;  Dolisca, S.-B.;  Bolduc, A. 
K.;  Hoang, K.;  Ashley, C.;  McCall, D.;  Rojiani, A. M.;  Maria, B. L.;  Rixe, O.;  
MacDonald, T. J.;  Heeger, P. S.;  Mellor, A. L.;  Munn, D. H.; Johnson, T. S., The 
indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of 
83 
 
chemo-radiation therapy against murine glioblastoma. Journal for ImmunoTherapy of 
Cancer 2014, 2 (1), 21. 
128. Z. H. A. Nayak, R. S., R. Dobbins, L. Marshall, N. N. Vahanian, W. J. Ramsey, E. 
Kennedy, M. Mautino, C. Link, R. Lin, S. Royer-Joo, K. Morrissey, S. Mahrus, B. McCall, 
A. Pirzkall, J. E. J. D. H. Munn and S. N. Khleif, European Society for Medical Oncology, 
2015; pp 25–29. 
129. Iversen, T. Z.;  Engell-Noerregaard, L.;  Ellebaek, E.;  Andersen, R.;  Larsen, S. K.;  
Bjoern, J.;  Zeyher, C.;  Gouttefangeas, C.;  Thomsen, B. M.;  Holm, B.;  thor Straten, P.;  
Mellemgaard, A.;  Andersen, M. H.; Svane, I. M., Long-lasting Disease Stabilization in the 
Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope 
Derived from Indoleamine 2,3 Dioxygenase. Clinical Cancer Research 2014, 20 (1), 221-
232. 
130. Kjeldsen, J. W.;  Iversen, T. Z.;  Noerregaard, L. E.;  Mellemgaard, A.;  Andersen, 
M. H.; Svane, I. M., 1326PLong-term follow-up results of stage III-IV non-small-cell lung 
cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 
Dioxygenase (IDO) in a phase I study. Annals of Oncology 2017, 28 (suppl_5), 
mdx380.028-mdx380.028. 
131. Hyun Han, J.;  Eun Kwon, Y.;  Sohn, J.-H.; Hyun Ryu, D., A facile method for the 
rapid and selective deprotection of methoxymethyl (MOM) ethers. 2010; Vol. 66, p 1673-
1677. 
132. Isidro-Llobet, A.;  Álvarez, M.; Albericio, F., Amino Acid-Protecting Groups. 
Chemical Reviews 2009, 109 (6), 2455-2504. 
133. S Lin, L.;  Lanza, T.;  E de Laszlo, S.;  Truong, Q.;  Kamenecka, T.; Hagmann, W., 
Deprotection of N-tert-Butoxycarbonyl (Boc) Groups in the Presence of tert-Butyl Esters. 
2000; Vol. 41, p 7013-7016. 
134. Curran, T. P.;  Pollastri, M. P.;  Abelleira, S. M.;  Messier, R. J.;  McCollum, T. A.; 
Rowe, C. G., Loss of the tert-butyloxycarbonyl (Boc) protecting group under basic 
conditions. Tetrahedron Letters 1994, 35 (30), 5409-5412. 
135. Ravinder, K.;  Reddy, A. V.;  Mahesh, K. C.;  Narasimhulu, M.; Venkateswarlu, 
Y., Simple and Selective Removal of the t‐Butyloxycarbonyl (Boc) Protecting Group on 
Indoles, Pyrroles, Indazoles, and Carbolines. Synthetic Communications 2007, 37 (2), 281-
287. 
136. Neelarapu, R.; Petukhov, P. A., A one-pot selective synthesis of N-Boc protected 
secondary amines: tandem direct reductive amination/N-Boc protection. Tetrahedron 
2012, 68 (35), 7056-7062. 
137. Liu, Y.-S.;  Zhao, C.;  Bergbreiter, D. E.; Romo, D., Simultaneous Deprotection 
and Purification of BOC-amines Based on Ionic Resin Capture. The Journal of Organic 
Chemistry 1998, 63 (10), 3471-3473. 
138. Jahani, F.;  Tajbakhsh, M.;  Khaksar, S.; Azizi, M. R., An efficient and highly 
chemoselective N-Boc protection of amines, amino acids, and peptides under 
heterogeneous conditions. Monatshefte für Chemie - Chemical Monthly 2011, 142 (10), 
1035. 
139. Chankeshwara, S. V.; Chakraborti, A. K., Catalyst-Free Chemoselective N-tert-
Butyloxycarbonylation of Amines in Water. Organic Letters 2006, 8 (15), 3259-3262. 
84 
 
140. Heydari, A.;  Khaksar, S.; Tajbakhsh, M., 1,1,1,3,3,3-Hexafluoroisopropanol: A 
Recyclable Organocatalyst for N-Boc Protection of Amines. Synthesis 2008, 2008 (19), 
3126-3130. 
141. Majumdar, S.;  De, J.;  Chakraborty, A.; Maiti, D. K., General solvent-free highly 
selective N-tert-butyloxycarbonylation strategy using protic ionic liquid as an efficient 
catalyst. RSC Advances 2014, 4 (47), 24544-24550. 
142. Amira, A.;  K’tir, H.;  Berredjem, M.; Aouf, N.-E., A simple, rapid, and efficient 
N-Boc protection of amines under ultrasound irradiation and catalyst-free conditions. 
Monatshefte für Chemie - Chemical Monthly 2014, 145 (3), 509-515. 
143. Varala, R.;  Nuvula, S.; Adapa, S. R., Molecular Iodine-Catalyzed Facile Procedure 
for N-Boc Protection of Amines. The Journal of Organic Chemistry 2006, 71 (21), 8283-
8286. 
144. López-Soria, J. M.;  Pérez, S. J.;  Hernández, J. N.;  Ramírez, M. A.;  Martín, V. 
S.; Padrón, J. I., A practical, catalytic and selective deprotection of a Boc group in N,N′-
diprotected amines using iron(iii)-catalysis. RSC Advances 2015, 5 (9), 6647-6651. 
145. Marcantoni, E.;  Massaccesi, M.;  Torregiani, E.;  Bartoli, G.;  Bosco, M.; Sambri, 
L., Selective Deprotection of N-Boc-Protected tert-Butyl Ester Amino Acids by the 
CeCl3·7H2O−NaI System in Acetonitrile. The Journal of Organic Chemistry 2001, 66 
(12), 4430-4432. 
146. Subhas Bose, D.;  Kiran Kumar, K.; Narsimha Reddy, A. V., A New Protocol for 
Selective Deprotection of N - tert -Butoxycarbonyl Protective Group ( t -Boc) with 
Sn(OTf)2. Synthetic Communications 2003, 33 (3), 445-450. 
147. Nudelman, A.;  Bechor, Y.;  Falb, E.;  Fischer, B.;  Wexler, B.; Nudelman, A., 
Acetyl Chloride—Methanol as a Convenient Reagent for: A) Quantitative Formation of 
Amine Hydrochlorides, B) Carboxylate Ester Formation, C) Mild Removal of N-Boc-
Protective Group. Synthetic Communications 1998, 28, 471-474. 
148. Gibson, F. S.;  Bergmeier, S. C.; Rapoport, H., Selective Removal of an N-BOC 
Protecting Group in the Presence of a tert-Butyl Ester and Other Acid-Sensitive Groups. 
The Journal of Organic Chemistry 1994, 59 (11), 3216-3218. 
149. Han, G.;  Tamaki, M.; Hruby, V. J., Fast, efficient and selective deprotection of the 
tert-butoxycarbonyl (Boc) group using HCl/dioxane (4 m). The Journal of Peptide 
Research 2001, 58 (4), 338-341. 
150. Coffey, D. S.;  Hawk, M. K. N.;  Ghera, S. J.;  Marler, P. G.;  Dodson, P. N.; Lytle, 
M. L., Large Scale Deprotection of a tert-Butoxycarbonyl (Boc) Group Using Aqueous 
HCl and Acetone. Organic Process Research & Development 2004, 8 (6), 945-947. 
151. Li, B.;  Berliner, M.;  Buzon, R.;  Chiu, C. K. F.;  Colgan, S. T.;  Kaneko, T.;  Keene, 
N.;  Kissel, W.;  Le, T.;  Leeman, K. R.;  Marquez, B.;  Morris, R.;  Newell, L.;  
Wunderwald, S.;  Witt, M.;  Weaver, J.;  Zhang, Z.; Zhang, Z., Aqueous Phosphoric Acid 
as a Mild Reagent for Deprotection of tert-Butyl Carbamates, Esters, and Ethers. The 
Journal of Organic Chemistry 2006, 71 (24), 9045-9050. 
152. Li, B.;  Bemish, R.;  Buzon, R. A.;  Chiu, C. K. F.;  Colgan, S. T.;  Kissel, W.;  Le, 
T.;  Leeman, K. R.;  Newell, L.; Roth, J., Aqueous phosphoric acid as a mild reagent for 
deprotection of the t-butoxycarbonyl group. Tetrahedron Letters 2003, 44 (44), 8113-8115. 
153. Wang, J.;  Liang, Y.-L.; Qu, J., Boiling water-catalyzed neutral and selective N-
Boc deprotection. Chemical Communications 2009,  (34), 5144-5146. 
85 
 
154. apelqvist, T.; Wensbo, D., Selective removal of the N-BOC protective group using 
silica gel at low pressure. Tetrahedron Letters 1996, 37 (9), 1471-1472. 
155. Pavan Kumar, G.;  Rambabu, D.;  Basaveswara Rao, M. V.; Pal, M., Iodine-
Mediated Neutral and Selective <i>N</i>-Boc Deprotection. Journal of Chemistry 2013, 
2013, 916960. 
156. Nadia, K.;  Malika, B.;  Nawel, K.;  Yazid, B. M.;  Zine, R.; Aouf, N.-E., Simple 
and efficient cleavage reaction of the boc group in heterocyclic compounds. Journal of 
Heterocyclic Chemistry 2004, 41 (1), 57-60. 
157. El Kazzouli, S.;  Koubachi, J.;  Berteina-Raboin, S.;  Mouaddib, A.; Guillaumet, 
G., A mild and selective method for the N-Boc deprotection by sodium carbonate. 
Tetrahedron Letters 2006, 47 (48), 8575-8577. 
158. Tom, N. J.;  Simon, W. M.;  Frost, H. N.; Ewing, M., Deprotection of a primary 
Boc group under basic conditions. Tetrahedron Letters 2004, 45 (5), 905-906. 
159. Dandepally, S. R.; Williams, A. L., Microwave-assisted N-Boc deprotection under 
mild basic conditions using K3PO4·H2O in MeOH. Tetrahedron Letters 2009, 50 (9), 
1071-1074. 
160. Wang, G.;  Li, C.;  Li, J.; Jia, X., Catalyst-free water-mediated N-Boc deprotection. 
Tetrahedron Letters 2009, 50 (13), 1438-1440. 
161. Li, B.;  Li, R.;  Dorff, P.;  McWilliams, J. C.;  Guinn, R. M.;  Guinness, S. M.;  Han, 
L.;  Wang, K.; Yu, S., Deprotection of N-Boc Groups under Continuous-Flow High-
Temperature Conditions. The Journal of Organic Chemistry 2019, 84 (8), 4846-4855. 
162. Choy, J.;  Jaime-Figueroa, S.;  Jiang, L.; Wagner, P., Novel Practical Deprotection 
of N-Boc Compounds Using Fluorinated Alcohols. Synthetic Communications 2008, 38 
(21), 3840-3853. 
163. Liu, Z.;  Yasuda, N.;  Simeone, M.; Reamer, R. A., N-Boc Deprotection and 
Isolation Method for Water-Soluble Zwitterionic Compounds. The Journal of Organic 
Chemistry 2014, 79 (23), 11792-11796. 
164. Larsen, R. D.;  Reamer, R. A.;  Corley, E. G.;  Davis, P.;  Grabowski, E. J. J.;  
Reider, P. J.; Shinkai, I., A modified Bischler-Napieralski procedure for the synthesis of 3-
aryl-3,4-dihydroisoquinolines. The Journal of Organic Chemistry 1991, 56 (21), 6034-
6038. 
165. Koenig, S. G.;  Vandenbossche, C. P.;  Zhao, H.;  Mousaw, P.;  Singh, S. P.; Bakale, 
R. P., A Facile Deprotection of Secondary Acetamides. Organic Letters 2009, 11 (2), 433-
436. 
166. Ofori, S.; Awuah, S. G., Small-Molecule Poly(ADP-ribose) Polymerase and PD-
L1 Inhibitor Conjugates as Dual-Action Anticancer Agents. ACS Omega 2019, 4 (7), 
12584-12597. 
167. Flekhter, O. B.;  Boreko, E. I.;  Nigmatullina, L. R.;  Tret'iakova, E. V.;  Pavlova, 
N. I.;  Baltina, L. A.;  Nikolaeva, S. N.;  Savinova, O. V.;  Galin, F. Z.; Tolstikov, G. A., 
[Synthesis and antiviral activity of ureides and carbamates of betulinic acid and its 
derivatives]. Bioorg Khim 2003, 29 (6), 655-61. 
168. Finke, P. E.;  Shah, S. K.;  Fletcher, D. S.;  Ashe, B. M.;  Brause, K. A.;  Chandler, 
G. O.;  Dellea, P. S.;  Hand, K. M.; Maycock, A. L., Orally Active .beta.-Lactam Inhibitors 
of Human Leukocyte Elastase. 3. Stereospecific Synthesis and Structure-Activity 




169. Rekker, R. F.; Nauta, W. T., The alkaline hydrolysis of oxazolidinediones-2,4. 
Recueil des Travaux Chimiques des Pays-Bas 1960, 79 (8), 843-853. 
170. Clark-Lewis, J. W., 2,4-Oxazolidinediones. Chemical Reviews 1958, 58 (1), 63-99. 
171. Ellames, G. J.;  Gibson, J. S.;  Herbert, J. M.; McNeill, A. H., The scope and 
limitations of deuteration mediated by Crabtree's catalyst. Tetrahedron 2001, 57 (46), 
9487-9497. 
172. Voth, S.;  Hollett, J. W.; McCubbin, J. A., Transition-Metal-Free Access to Primary 
Anilines from Boronic Acids and a Common +NH2 Equivalent. The Journal of Organic 
Chemistry 2015, 80 (5), 2545-2553. 
173. Deb, B.;  Debnath, S.;  Deb, A.;  Maiti, D. K.; Majumdar, S., Copper nanoparticles 
catalyzed N-H functionalization: An efficient solvent-free N-tert-butyloxycarbonylation 
strategy. Tetrahedron Letters 2017, 58 (7), 629-633. 
174. Du, J.;  Chen, J.;  Xia, H.;  Zhao, Y.;  Wang, F.;  Liu, H.;  Zhou, W.; Wang, B., 
Commercially Available CuO Catalyzed Hydrogenation of Nitroarenes Using Ammonia 
Borane as a Hydrogen Source. ChemCatChem 2020, 12 (9), 2426-2430. 
175. Azizi, N.; Shirdel, F., Sustainable and chemoselective N-Boc protection of amines 
in biodegradable deep eutectic solvent. Monatshefte für Chemie - Chemical Monthly 2017, 
148 (6), 1069-1074. 
176. Rai, R. K.;  Mahata, A.;  Mukhopadhyay, S.;  Gupta, S.;  Li, P.-Z.;  Nguyen, K. T.;  
Zhao, Y.;  Pathak, B.; Singh, S. K., Room-Temperature Chemoselective Reduction of Nitro 
Groups Using Non-noble Metal Nanocatalysts in Water. Inorganic Chemistry 2014, 53 (6), 
2904-2909. 
177. Sarkar, A.;  Roy, S. R.;  Parikh, N.; Chakraborti, A. K., Nonsolvent Application of 
Ionic Liquids: Organo-Catalysis by 1-Alkyl-3-methylimidazolium Cation Based Room-
Temperature Ionic Liquids for Chemoselective N-tert-Butyloxycarbonylation of Amines 
and the Influence of the C-2 Hydrogen on Catalytic Efficiency. The Journal of Organic 
Chemistry 2011, 76 (17), 7132-7140. 
178. Egbert, J. D.;  Thomsen, E. C.;  O’Neill-Slawecki, S. A.;  Mans, D. M.;  Leitch, D. 
C.;  Edwards, L. J.;  Wade, C. E.; Weber, R. S., Development and Scale-up of Continuous 
Electrocatalytic Hydrogenation of Functionalized Nitro Arenes, Nitriles, and Unsaturated 
Aldehydes. Organic Process Research & Development 2019, 23 (9), 1803-1812. 
179. Kumarasamy, E.;  Raghunathan, R.;  Kandappa, S. K.;  Sreenithya, A.;  Jockusch, 
S.;  Sunoj, R. B.; Sivaguru, J., Transposed Paternò–Büchi Reaction. Journal of the 
American Chemical Society 2017, 139 (2), 655-662. 
180. Shuai, Q.;  Li, J.;  Zhao, F.;  Su, W.; Deng, G., Metal-free chemoselective reduction 
of nitroaromatics to anilines via hydrogen transfer strategy. Chemical Papers 2019, 73 (4), 
965-975. 
181. Lim, D. S. W.;  Lew, T. T. S.; Zhang, Y., Direct Amidation of N-Boc- and N-Cbz-
Protected Amines via Rhodium-Catalyzed Coupling of Arylboroxines and Carbamates. 
Organic Letters 2015, 17 (24), 6054-6057. 
182. Liu, L.;  Wang, Q.;  Liu, Y.;  Zhang, X.;  Lu, D.;  Deng, S.;  Gao, Y.; Chen, Y., 
Copper catalyzed reduction of azides with diboron under mild conditions. Tetrahedron 
Letters 2020, 61 (14), 151702. 
183. Mehndiratta, S.;  Lin, M. H.;  Wu, Y. W.;  Chen, C. H.;  Wu, T. Y.;  Chuang, K. 
H.;  Chao, M. W.;  Chen, Y. Y.;  Pan, S. L.;  Chen, M. C.; Liou, J. P., N-alkyl-
87 
 
hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, 
downregulating IFN-γ induced PD-L1 expression. Eur J Med Chem 2020, 185, 111725. 
184. Jiang, S.;  Dong, X.;  Qiu, Y.;  Chen, D.;  Wu, X.; Jiang, S., A new ligand for 
copper-catalyzed amination of aryl halides to primary(hetero)aryl amines. Tetrahedron 
Letters 2020, 61 (13), 151683. 
185. Zhang, D.;  Raghavan, N.;  Chen, S. Y.;  Zhang, H.;  Quan, M.;  Lecureux, L.;  
Patrone, L. M.;  Lam, P. Y.;  Bonacorsi, S. J.;  Knabb, R. M.;  Skiles, G. L.; He, K., 
Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic 
clearance pathway in rats and dogs. Drug Metab Dispos 2008, 36 (2), 303-15. 
186. Malpani, Y. R.;  Biswas, B. K.;  Han, H. S.;  Jung, Y.-S.; Han, S. B., 
Multicomponent Oxidative Trifluoromethylation of Alkynes with Photoredox Catalysis: 
Synthesis of α-Trifluoromethyl Ketones. Organic Letters 2018, 20 (7), 1693-1697. 
187. Ahmad, M. S.;  He, H.; Nishina, Y., Selective Hydrogenation by Carbocatalyst: 
The Role of Radicals. Organic Letters 2019, 21 (20), 8164-8168. 
188. Yoon, H.; Lee, Y., Copper-Catalyzed Electrophilic Amination of Heteroarenes via 
C–H Alumination. The Journal of Organic Chemistry 2015, 80 (20), 10244-10251. 
189. Ageshina, A. A.;  Sterligov, G. K.;  Rzhevskiy, S. A.;  Topchiy, M. A.;  Chesnokov, 
G. A.;  Gribanov, P. S.;  Melnikova, E. K.;  Nechaev, M. S.;  Asachenko, A. F.; Bermeshev, 
M. V., Mixed er-NHC/phosphine Pd(ii) complexes and their catalytic activity in the 
Buchwald–Hartwig reaction under solvent-free conditions. Dalton Transactions 2019, 48 
(10), 3447-3452. 
190. Hyodo, K.;  Hasegawa, G.;  Maki, H.; Uchida, K., Deacetylative Amination of 
Acetyl Arenes and Alkanes with C-C Bond Cleavage. Org Lett 2019, 21 (8), 2818-2822. 
191. Liu, Y.;  Quan, Z.;  He, S.;  Zhao, Z.;  Wang, J.; Wang, B., Heterogeneous 
palladium-based catalyst promoted reduction of oximes to amines: using H2 at 1 atm in 
H2O under mild conditions. Reaction Chemistry & Engineering 2019, 4 (6), 1145-1152. 
192. Uvyn, A.;  De Coen, R.;  Gruijs, M.;  Tuk, C. W.;  De Vrieze, J.;  van Egmond, M.; 
De Geest, B. G., Efficient Innate Immune Killing of Cancer Cells Triggered by Cell-
Surface Anchoring of Multivalent Antibody-Recruiting Polymers. Angewandte Chemie 
International Edition 2019, 58 (37), 12988-12993. 
193. Akine, S.;  Onuma, T.; Nabeshima, T., A novel graphite-like stacking structure in 
a discrete molecule and its molecular recognition behavior. New Journal of Chemistry 
2018, 42 (12), 9369-9372. 
194. Alano, C. C.;  Garnier, P.;  Ying, W.;  Higashi, Y.;  Kauppinen, T. M.; Swanson, 
R. A., NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-
mediated neuronal death. J Neurosci 2010, 30 (8), 2967-2978. 
195. Hurtado-Bagès, S.;  Knobloch, G.;  Ladurner, A. G.; Buschbeck, M., The taming 
of PARP1 and its impact on NAD+ metabolism. Molecular Metabolism 2020, 38, 100950. 
196. Grant, R. S., Indoleamine 2,3-Dioxygenase Activity Increases NAD+ Production 
in IFN-γ–Stimulated Human Primary Mononuclear Cells. International Journal of 
Tryptophan Research 2018, 11, 1178646917751636. 
197. Maleki Vareki, S.;  Rytelewski, M.;  Figueredo, R.;  Chen, D.;  Ferguson, P. J.;  
Vincent, M.;  Min, W.;  Zheng, X.; Koropatnick, J., Indoleamine 2,3-dioxygenase mediates 
immune-independent human tumor cell resistance to olaparib, gamma radiation, and 
cisplatin. Oncotarget 2014, 5 (9), 2778-2791. 
88 
 
198. Kim, J. H.;  Reeder, E.;  Parkin, S.; Awuah, S. G., Gold(I/III)-Phosphine Complexes 








Place of birth: 
San Juan, Trinidad & Tobago 
Degrees 
Master of Science in Chemistry – University of Kentucky, Lexington KY, May 2021 
(expected) 
Bachelor of Arts in Chemistry – Grinnell College, Grinnell, IA. May 2015 
Professional positions held: 
Quality Control Analyst – Catalent Pharma Solutions, Winchester KY. June 2018–May 
2019 
Chemist I – Piramal Pharma Solutions, Lexington KY. Jan 2021 – Present 
Scholastic and professional honors: 
Charles H.H. Griffith Outstanding General Chemistry Teaching Assistant Award              
May 2017 
Professional publications: 
“Mild deprotection of the N-tert-butyloxycarbonyl (N-Boc) group using oxalyl chloride” 
RSC Adv., 2020,10, 24017-24026 
Nathaniel Hugh George 
